

# Article Characterization of Metal-Specific T-Cells in Inflamed Oral Mucosa in a Novel Murine Model of Chromium-Induced Allergic Contact Dermatitis

Takamasa Yoshizawa <sup>1,2,†</sup>, Kenichi Kumagai <sup>2,3,†</sup>, Ryota Matsubara <sup>2,4</sup>, Keisuke Nasu <sup>1,2</sup>, Kazutaka Kitaura <sup>2,5</sup>, Motoaki Suzuki <sup>2,6</sup>, Yoshiki Hamada <sup>1,\*</sup> and Ryuji Suzuki <sup>2,5</sup>

- <sup>1</sup> Department of Oral and Maxillofacial Surgery, School of Dental Medicine, Tsurumi University, Yokohama 230-8501, Japan
- <sup>2</sup> Department of Rheumatology and Clinical Immunology, Clinical Research Center for Rheumatology and Allergy, Sagamihara National Hospital, National Hospital Organization, Sagamihara 252-0392, Japan
- <sup>3</sup> Department of Oral and Maxillofacial Surgery, Dentistry and Orthodontics, The University of Tokyo Hospital, Tokyo 113-8655, Japan
- <sup>4</sup> Department of Oral and Maxillofacial Surgery, Sendai Tokushukai Hospital, Sendai 981-3116, Japan
- <sup>5</sup> Repertoire Genesis Inc., Osaka 567-0085, Japan
- <sup>6</sup> Department of Anatomy and Physiology, Faculty of Medicine, Saga University, Saga 849-8501, Japan
- Correspondence: hamada-y@tsurumi-u.ac.jp; Tel./Fax: +81-45-580-8327
- + These authors contributed equally to this work.

Abstract: The element chromium (Cr) is a component of several types of alloys found in the environment, or utilized in dentistry, that may cause intraoral metal contact allergy. However, the pathological mechanism of intraoral Cr allergy remains unclear because there is no established animal model of Cr allergy in the oral mucosa. In this study, we established a novel murine model of Cr-induced intraoral metal contact allergy and elucidated the immune response in terms of cytokine profiles and T-cell receptor repertoire. Two sensitizations with Cr plus lipopolysaccharide solution into the postauricular skin were followed by a single Cr challenge of the oral mucosa to generate the intraoral metal contact allergy model. Histological examination revealed that CD3+ T-cells had infiltrated the allergic oral mucosa one day after exposure to the allergen. The increase in T-cell markers and cytokines in allergic oral mucosa was also confirmed via quantitative PCR analysis. We detected Cr-specific T-cells bearing TRAV12D-1-TRAJ22 and natural killer (NK) T-cells in the oral mucosa and lymph nodes. Our model demonstrated that Cr-specific T-cells and potent NKT-cell activation may be involved in the immune responses of Cr-induced intraoral metal contact allergy.

Keywords: chromium allergy; contact dermatitis; allergic contact mucositis; metal allergy

# 1. Introduction

Metal allergy is categorized as a delayed-type hypersensitivity (DTH) reaction triggered by antigenic protein with haptens that exert antigenicity. It can be caused by metal ions released by jewelry, footwear, preservatives, and cosmetics [1]. In addition to nickel (Ni), cobalt (Co), palladium (Pd), zinc (Zn), and chromium (Cr) have been reported to cause allergic contact dermatitis [2–5]. Cr hypersensitivity is one of the most prevalent occupational metal skin diseases in cement workers [6]. Occupational allergic contact dermatitis was the most frequently occurring allergy in construction workers (45%), and the most frequent allergen was chromium (Cr) in cement [6,7]. In addition, the production of a chronic generalized eczematoid reaction has been reported as a causal intraoral Cr-allergic contact dermatitis [8]. Recently, Cr has been widely used in dental restorations such as implants, crown prostheses, and dentures. However, the pathological mechanism of intraoral Cr allergy remains unknown because there is no established animal model of Cr allergy in the oral mucosa. According to previous studies of murine models of DTH in the oral



Citation: Yoshizawa, T.; Kumagai, K.; Matsubara, R.; Nasu, K.; Kitaura, K.; Suzuki, M.; Hamada, Y.; Suzuki, R. Characterization of Metal-Specific T-Cells in Inflamed Oral Mucosa in a Novel Murine Model of Chromium-Induced Allergic Contact Dermatitis. *Int. J. Mol. Sci.* 2023, 24, 2807. https://doi.org/10.3390/ ijms24032807

Academic Editor: Shun-Fa Yang

Received: 27 December 2022 Revised: 23 January 2023 Accepted: 29 January 2023 Published: 1 February 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). mucosa, various chemicals, such as oxazolone (4-ethoxymethylene-2-phenyloxazol-5-one) and 2,4-dinitro-1-fluorobenzene, induce allergic contact mucositis (ACM) with the local accumulation of antigen-presenting cells and T-cells [9].

Typically, metal allergy is associated with acquired immunity, which facilitates the migration of metal-specific T-cells to the site of allergic inflammation. T-cells recognize antigens on antigen-presenting cells through surface-expressed T-cell receptors (TCRs), heterodimers composed of an  $\alpha$ - and  $\beta$ -chain (TRA and TRB) that determine the high specificity of T-cells [10]. In previous studies, the cells in the peripheral blood and skin of patients with metal allergy had limited TCR repertoires [11]. Several novel murine models of Ni, Pd, Cr, and titanium (Ti)-induced allergic contact dermatitis (ACD) have been generated using footpad skin, and these have aided in the characterization of antigen-specific immune responses in terms of TCR usage [12–15]. These models enabled us to identify the accumulation of metal-specific T-cells in inflamed skin and to demonstrate that the restricted usage of TCR genes in metal allergy is a result of the prolonged exposure of the host immune system to putative metal-associated antigens. The analysis of the TCR repertoire enables the identification of antigen-specific T-cells [16]. Recent advances in next-generation sequencing (NGS) have permitted the quantitative analyses of the TCR repertoire using large amounts of TCR sequencing data [17,18].

In the present study, we established a novel murine model of Cr-induced allergy in the oral mucosa to examine how the accumulation of T-cells at the site of allergic inflammation contributes to the development of Cr allergy in the oral mucosa and how TCR gene usage is regulated.

# 2. Results

#### 2.1. Oral Mucosa Swelling in Cr-Induced Allergic Mice

At Day 1 post-challenge, maximal swelling in the buccal area of the oral mucosa occurred in all mice (Figure 1). At Day 7 post-challenge, the swelling of the oral mucosa was significantly greater in the ACM mice than in the control mice, but it was not significantly different in irritant contact mucositis (ICM) mice. From Days 1 to 12 post-challenge, oral mucosa swelling in the ACM mice was greater than in the control mice.



**Figure 1.** Swelling of the oral mucosa in Cr-induced allergic mice. The oral mucosa of all mice reached maximal swelling at Day 1 post-challenge. The oral mucosa swelled significantly more in the ACM mice from Days 1 to 12 post-challenge compared with the control mice. The bars and error bars represent the mean plus the standard deviation. The Kruskal–Wallis test was used to determine statistical significance, followed by Dunn's multiple comparison tests (\* *p* < 0.05, \*\* *p* < 0.01, \*\*\* *p* < 0.001).

#### 2.2. Histological and Immunohistochemical Analyses of F4/80 and CD3 in the Oral Mucosa of Cr-Induced Allergic Mice

To determine whether macrophages and T-cells infiltrated the inflamed oral mucosa, histological and immunohistochemical (IHC) analyses were performed on the oral mucosa of the control, ICM, and ACM mice at Days 1 and 7 post-challenge. Hematoxylin and eosin (HE) staining revealed dense infiltration of inflammatory cells in the basal epithelial layer and upper dermis, in addition to a swelling of the oral mucosa, in the ACM and ICM mice, but not in the control mice (Figure 2A–E). Inflammatory cells accumulated in the epithelium and upper dermis of the ACM mice (Figure 2D). The partial separation of epidermal keratinocytes produced spongiotic dermatitis (Figure 2D). In the ICM mice, the inflammatory response in the oral mucosa was reduced (Figure 2B,C). In contrast, inflammation of the oral mucosa persisted for Day 7 post-challenge in the ACM mice (Figure 2E). We performed the IHC staining of CD3 and F4/80 in the oral mucosa of the control, ICM, and ACM mice to determine whether T-cells and macrophages had infiltrated the inflamed oral mucosa of the ACM mice (Figure 2F-O). Significant CD3+ T-cell infiltration occurred into the basal epithelial layer and upper dermis of the ACM mice by Day 1 post-challenge compared with the control and ICM mice (Figure 2F,G,I). The ACM mice retained CD3+ T-cells in the basal epithelial layer and upper dermis Day 7 post-challenge (Figure 2J). There was little infiltration of CD3+ T-cells into the basal epithelial layer and upper dermis of the control and ICM mice (Figure 2F–H). At Day 1 post-challenge, F4/80+ macrophages were predominant in the layer and upper dermis of the ACM mice (Figure 2N), but not in the control and ICM mice (Figure 2K,L,M,O).

#### 2.3. mRNA Expression of T-Cell Markers in the Oral Mucosa of Cr-Induced Allergic Mice

We performed quantitative polymerase chain reaction (qPCR) of CD3, CD4, and CD8 to verify the infiltration of T-cells into the inflamed oral mucosa and determine their relative mRNA expression. CD3 expression in the ACM mice was significantly higher than in the control and ICM mice at Days 1 and 7 post-challenge (Figure 3). At Day 1 post-challenge, the CD8/CD4 ratio was significantly higher in the ACM mice than in the control and ICM mice (Figure 3).

# 2.4. Relative mRNA Expression of T-Cell-Related Cytokines in the Oral Mucosa of Cr-Induced Allergic Mice

Subsequently, using qPCR analysis, the mRNA expression of inflammatory markers was analyzed to examine inflammation in the allergic oral mucosa. We compared the expression levels of a proinflammatory cytokine (IL-1 $\beta$ ), a Th1-related gene (IFN- $\gamma$ ), a Th2-related gene (IL-4), and the serine protease(granzyme B) in the oral mucosa of the control, ICM, and ACM mice using qPCR (Figure 4). At Days 1 and 7 post-challenge, IL-1 $\beta$  and granzyme B expression levels were significantly higher in the ACM mice than in the control and ICM mice. IFN- $\gamma$ , in contrast to IL-4, was significantly higher in the ACM mice relative to the ICM mice with similar expression maintained on Days 1 and 7.

#### 2.5. TCR Repertoire Usage in the Oral Mucosa and Cervical Lymph Nodes of the ICM and ACM Mice

We performed an NGS-based TCR repertoire analysis to determine the diversity of T-cells that had infiltrated the oral mucosa and cervical lymph nodes of the ICM and ACM mice at Day 1 post-challenge. A 3D representation of the TRA repertoire revealed the dominance of particular combinations of TRAV and TRAJ genes, as well as the breadth of TCR usage diversity (Figure 5). The 3D images of the TRA repertoire revealed a low level of expression accompanied by a broad distribution of TRAV and TRAJ. The usage of TRAV11d-TRAJ18 was considerably higher in the oral mucosa and cervical lymph nodes of the ICM and ACM mice († in Figure 5).



**Figure 2.** Histological and IHC analyses of CD3 and F4/80 in the oral mucosa of the control, ICM, and ACM mice. Histological and IHC analyses of CD3+ and F4/80+ T-cells in the oral mucosa at Days 1 and 7 post-challenge. At Day 1 post-challenge, the ACM mice exhibited abundant infiltration of mononuclear cells, swelling of the mucosal epithelium, and epidermal spongiosis (**D**), and IHC analyses revealed the presence of CD3+ T-cells in the epithelium of the ACM mice (**I**). Sections were stained with HE (**A**–**E**), CD3 (**F**–**J**), and F4/80 (**K**–**O**). Scale bar = 10 µm.



Figure 3. Cont.



**Figure 3.** mRNA expression of T-cell phenotypes in the oral mucosa of Cr-induced allergic mice. At Days 1 and 7 post-challenge, the mRNA expression of CD3, CD4, CD8, and the CD8/CD4 ratio in the oral mucosa was evaluated (n = 8). The expression of the GAPDH gene served as an internal control. The mean and standard deviation are represented by bars and error bars. Kruskal–Wallis and Dunn's multiple comparison tests were used to determine statistical significance (\* p < 0.05, \*\* p < 0.01).



**Figure 4.** mRNA expression of T-cell-related cytokines in control, ICM, and ACM mice. At Days 1 and 7 post-challenge, the mRNA expression levels of IL-1 $\beta$ , IFN- $\gamma$ , IL-4, and granzyme B in the oral mucosa (n = 8) were evaluated. The expression of the GAPDH gene served as an internal control. The mean and standard deviation are represented by bars and error bars, respectively. Kruskal–Wallis and Dunn's multiple comparison tests were used to determine the statistical significance of differences (\* *p* < 0.05, \*\* *p* < 0.01, N.S. = not significant).



**Figure 5.** TCR repertoire in the oral mucosa and cervical lymph nodes of the ICM and ACM mice. NGS-based TCR repertoire analysis was performed on the oral mucosa and cervical lymph nodes of the ICM and ACM mice at Day 1 post-challenge (n = 6). Additionally, at Day 1 post-challenge, 3D images of the TCR repertoire depict the skewing of T-cells infiltrating the oral mucosa and cervical lymph nodes of the ICM and ACM mice. Combining TRAV on the X-axis and TRAJ on the Z-axis, with the frequency (percentage) of each clone on the Y-axis, the 3D images depict the TCR repertoire. +: TRAs bearing TRAV11d-TRAJ18. OM: oral mucosa. LY: lymph nodes of the cervical region.

Next, we analyzed the CDR3 amino acid sequences shared by the ICM and the ACM mice (Figure 6). Notably, the proportion of T-cells bearing TCR TRAV11d-TRAJ18 (CVVG-DRGSALGRLHF) was highest in the oral mucosa and cervical lymph nodes (Figure 6, green shading) compared with other T-cells. In mice, invariant natural killer T (iNKT) cells express a TRA encoded by the gene segments TRAV11d-TRAJ18 [19]. T-cells bearing TRAV12D-1-TRAJ22 (Figure 6, yellow shading) with common CDR3 amino acid sequences (CALSEKSSGSWQLIF) were detected frequently in the oral mucosa and cervical lymph nodes of the ACM mice but in only a few cervical lymph nodes of the ICM mice. Furthermore, to identify changes in the T-cell diversity at Days 1, 3, and 7 postchallenge, we examined the TCR repertoire of T-cells in Cr allergy that had infiltrated the oral mucosa of the ACM mice at Days 3 and 7 post-challenge (Figure S1). The frequency ranking of TRA clonotypes for the top 30 read percentages indicated a high proportion of iNKT-cells in the oral mucosa of the ACM mice at Days 3 and 7 post-challenge (Figure S1, green shading). T-cells bearing TRAV1-TRAJ33 with common CDR3 amino acid sequences (CAVRDSNYQLIW) were detected in the oral mucosa of the ACM mice between Days 3 and 7 post-challenge (Figure S1, blue shading). Mucosal-associated invariant T (MAIT) cells in mice express a TRA encoded by the TRAV1-TRAJ33 gene segments [19]. Next, we examined the common CDR3 amino acid sequences in the TRB repertoire in the ACM mice (Figure S2). There was no shared TRB clone in the sequences from the inflamed oral mucosa of the ACM mice at Days 1, 3, and 7 post-challenge.

	TRA Ranking Top1-30 of oral mucosa in the ICM Day1					TRA Ranking Top1-30 of cervical lymph nodes in the ICM Day1				
Rank	TRAV	TRAJ	CDR3	%Reads	Rank	TRAV	TRAJ	CDR3	%Reads	
1	TRAV11D	TRAJ18	CVVGDRGSALGRLHF(iNKT)	2.57	1	TRAV11D	TRAJ18	CVVGDRGSALGRLHF(iNKT)	0.26	
2	TRAV7D-2	TRAJ30	CAASYDTNAYKVIF	2.48	2	TRAV4-4/DV10	TRAJ21	CAAEQPNYNVLYF	0.20	
3	TRAV14D-3/DV8	TRAJ43	CAASNNNNAPRF	2.24	3	TRAV9-4	TRAJ27	CAVSKITNTGKLTF	0.16	
4	TRAV1	TRAJ33	CAVRDSNYQLIW	2.12	4	TRAV7-5	TRAJ22	CAMEASGSWQLIF	0.08	
5	TRAV6-7/DV9	TRAJ56	CALSTGGNNKLTF	1.90	5	TRAV7D-2	TRAJ27	CAASDTNTGKITF	0.08	
6	TRAV9D-2	TRAJ27	CAVSARTNTGKLTF	1.87	6	TRAV6-5	TRAJ33	CALSGTDSNYQLIW	0.07	
7	TRAV17	TRAJ37	CALEAGNTRKLIF	1.79	7	TRAV6D-7	TRAJ30	CALLGTNAYKIIF	0.07	
8	TRAV6D-6	TRAJ49	CALTSNTGYQNFYF	1.70	8	TRAV9-3	TRAJ34	CAVGPSSSNTDKVVF	0.06	
9	TRAV12-2	TRAJ56	CALKTGGNNKLTF	1.69	9	TRAV14-1	TRAJ40	CAARSVNTGNYKNVF	0.06	
10	TRAV4-2	TRAJ17	CAASNSAGNKLTF	1.59	10	TRAV7-6	TRAJ52	CGGKANTGANTGKLTF	0.05	
11	TRAV13D-1	TRAJ43	CAMERNNNNAPRF	1.51	11	TRAV6-1	TRAJ33	CVLGHSNYQMIW	0.04	
12	TRAV16D/DV11	TRAJ13	CAMREDDSGTYQRF	1.45	12	TRAV6N-5	TRAJ9	CARGSAMGYKLTF	0.04	
13	TRAV6-5	TRAJ52	CALSDDTGANTGKLTF	1.35	13	TRAV7-3	TRAJ52	CAVSMITGANAGKLTF	0.04	
14	TRAV6D-7	TRAJ22	CALSSSSGSWQLIF	1.23	14	TRAV6-7/DV9	TRAJ27	CALAYNTNTGKLTF	0.04	
15	TRAV9D-3	TRAJ37	CAVSQLTGNTRKLIF	1.22	15	TRAV15D-1/DV6D-1	TRAJ52	CALWEPTGANTEKLTF	0.04	
16	TRAV12-2	TRAJ43	CALSLNNNAPRF	1.12	16	TRAV1	TRAJ33	CANMDSNYQLIW	0.04	
17	TRAV17	TRAJ52	CALNTGANTGKLTF	1.11	17	TRAV6-5	TRAJ40	CALSPNTGNYKSVF	0.04	
18	TRAV5-1	TRAJ38	CSASRVGDNSKLIW	1.10	18	TRAV7D-2	TRAJ4	CAARLSGSFNKMTF	0.04	
19	TRAV4-4/DV10	TRAJ34	CAAEAGDKVVF	1.09	19	TRAV17	TRAJ50	CALETSSFSKLVF	0.03	
20	TRAV13D-1	TRAJ31	CAMGNNNNRIFF	1.06	20	TRAV1	TRAJ18	CAVRGGGSALGRLHF	0.03	
21	TRAV7D-5	TRAJ39	CAVSMRDAGAKLTF	1.01	21	TRAV7-3	TRAJ40	CAVTGNYKFVF	0.03	
22	TRAV9-3	TRAJ21	CAVKPNYNVLYF	0.95	22	TRAV7-3	TRAJ40	CAVTGSYKYVF	0.03	
23	TRAV6D-7	TRAJ31	CALSDKGYNNNRIFF	0.95	23	TRAV4D-3	TRAJ57	CAADGDQGGSAKLIF	0.03	
24	TRAV9-4	TRAJ39	CAVRINNAGAKLTF	0.93	24	TRAV9-3	TRAJ44	CAVFTGRGGKLTL	0.03	
25	TRAV10	TRAJ31	CAASKNNNNRIFF	0.92	25	TRAV8-2	TRAJ27	CATEPGTNTGKLTF	0.03	
26	TRAV7D-5	TRAJ33	CAVSNYQLIW	0.91	26	TRAV21/DV12	TRAJ57	CILRVVNQGGSAKLIF	0.03	
27	TRAV8D-1	TRAJ52	CAPCTGANTGKLTF	0.88	27	TRAV16D/DV11	TRAJ31	CAMREYNNNRVFF	0.03	
28	TRAV9D-1	TRAJ15	CAASPPTAYQGGRALIF	0.87	28	TRAV3D-3	TRAJ24	CAVRKTASLGKLQF	0.03	
29	TRAV9D-4	TRAJ13	CALSPNSGTYQRF	0.82	29	TRAV16D/DV11	TRAJ7	CAMRERDYSNNRLTL	0.03	
30	TRAV7D-5	TRAJ17	CAVSTGNSAGNKLTF	0.81	30	TRAV19	TRAJ33	CAAGLDSNYQLIW	0.03	
-	TRAV12D-1	TRAI22	CALSEKSSGSWOLIF	ND	88132	TRAV12D-1	TRAI22	CALSEKSSCSWOLIE	0.0088	
				14.2	00102	HUIT IED I		CHEDERCOODUQER	0.0000	
				11.2.	00102			Скызыкоосон дын	0.0000	
	TRA Ranking	; Top1-30 c	of oral mucosa in the ACM Day1		00102	TRA Ranking Top1	-30 of cer	vical lymph nodes in the ACM Day	1	
Rank	TRA Ranking TRAV	; Top1-30 c	of oral mucosa in the ACM Day1 CDR3	%Reads	Rank	TRA Ranking Top1	-30 of cer	vical lymph nodes in the ACM Day	1 %Reads	
Rank 1	TRA Ranking TRAV TRAV11D	Top1-30 c TRAJ TRAJ18	of oral mucosa in the ACM Day1 CDR3 CVVGDRGSALGRLHF(iNKT)	%Reads	Rank	TRA Ranking Top1 TRAV TRAV11D	-30 of cer TRAJ TRAJ18	vical lymph nodes in the ACM Day CDR3 CVVGDRGSALGRLHF(iNKT)	1 %Reads 0.22	
Rank	TRA Ranking TRAV11D TRAV12D-1	Top1-30 c TRAJ TRAJ18 TRAJ22	of oral mucosa in the ACM Day1 CDR3 CVVGDRGSALGRLHF(iNKT) CALSEKSSGSWQLIF	%Reads 2.29 1.49	Rank 1 2	TRA Ranking Top1 TRAV TRAV11D TRAV7-5	-30 of cer TRAJ TRAJ18 TRAJ2	vical lymph nodes in the ACM Day CDR3 CVVGDRGSALGRLHF(iNKT) CAMSMWRTGGLSGKLTF	1 %Reads 0.22 0.06	
<b>Rank</b> 1 2 3	TRA Ranking TRAV TRAV11D TRAV12D-1 TRAV10	Top1-30 c TRAJ TRAJ18 TRAJ22 TRAJ53	of oral mucosa in the ACM Day1 CDR3 CVVGDRGSALGRLHF(iNKT) CALSEKSSGSWQLIF CAARNSGGSNYKLTF	%Reads 2.29 1.49 1.23	Rank 1 2 3	TRA Ranking Top1 TRAV TRAV11D TRAV7-5 TRAV12-2	-30 of cer TRAJ TRAJ18 TRAJ2 TRAJ57	vical lymph nodes in the ACM Day CDR3 CVVGDRCSALGRLHF(iNKT) CAMSMWRTGGLSGKLTF CALLNQGGSAKLIF	1 %Reads 0.22 0.06 0.06	
Rank 1 2 3 4	TRA Ranking TRAV TRAV11D TRAV12D-1 TRAV10 TRAV6N-5	TRAJ18 TRAJ22 TRAJ53 TRAJ45	of oral mucosa in the ACM Day1 CDR3 CVVCDRCSALGRLHF(iNKT) CALSEKSSCSWQLIF CAARNSGGSNYKLTF CALVPNTGGADRLTF	%Reads 2.29 1.49 1.23 0.99	Rank           1           2           3           4	TRA Ranking Top1 TRAV TRAV11D TRAV7-5 TRAV12-2 TRAV16D/DV11	-30 of cer TRAJ TRAJ18 TRAJ2 TRAJ57 TRAJ33	vical lymph nodes in the ACM Day CDR3 CVVGDRCSALGRLHF(iNKT) CAMSMWRTGGLSGKLTF CALLNQGGSAKLIF CAMREGRVIW	1 %Reads 0.22 0.06 0.06 0.06	
Rank 1 2 3 4 5	TRA Ranking TRAV TRAV11D TRAV12D-1 TRAV10 TRAV6N-5 TRAV13D-1	TRAJ18 TRAJ18 TRAJ22 TRAJ53 TRAJ45 TRAJ32	of oral mucosa in the ACM Day1 CDR3 CVVGDRCSALGRLHF(INKT) CALSEKSSGSWQLIF CAARNSGGSNYKLTF CALVPNTGGADRLTF CAMEDYGGSGNKLIF	%Reads 2.29 1.49 1.23 0.99 0.92	Rank 1 2 3 4 5	TRA Ranking Top1 TRAV TRAV11D TRAV7-5 TRAV12-2 TRAV16D/DV11 TRAV6-6	-30 of cer TRAJ TRAJ18 TRAJ2 TRAJ57 TRAJ33 TRAJ40	vical lymph nodes in the ACM Day CDR3 CVVGDRCSALGRLHF(iNKT) CAMSMWRTGGLSGKLTF CALLNQGGSAKLIF CAMREGRVIW CALGDPGNYKYVF	1 %Reads 0.22 0.06 0.06 0.06 0.05	
Rank 1 2 3 4 5 6	TRA Ranking TRAV11D TRAV11D TRAV12D-1 TRAV10 TRAV10 TRAV6N-5 TRAV13D-1 TRAV13D-1	TRAJ18 TRAJ18 TRAJ22 TRAJ53 TRAJ45 TRAJ45 TRAJ32 TRAJ22	of oral mucosa in the ACM Day1 CDR3 CVVGDRGSALGRLHF(INKT) CALSEKSSGSWQLIF CALVPNTGGADRLTF CALVPNTGGADRLTF CAMEDYGCSGNKLIF CAASSSGSWQLIF	%Reads 2.29 1.49 1.23 0.99 0.92 0.80	Rank 1 2 3 4 5 6	TRA Ranking Top1 TRAV TRAV11D TRAV7-5 TRAV12-2 TRAV16D/DV11 TRAV6-6 TRAV16D/DV11	-30 of cer TRAJ TRAJ18 TRAJ2 TRAJ57 TRAJ33 TRAJ40 TRAJ31	vical lymph nodes in the ACM Day CDR3 CVVGDRGSALGRLHF(iNKT) CAMSMWRTGGLSGKLIF CALLNQGGSAKLIF CAMREGRVIW CALGDPCNYKYVF CAMREYNNNRVFF	1 %Reads 0.22 0.06 0.06 0.06 0.06 0.05 0.04	
Rank 1 2 3 4 5 6 7	TRA Ranking TRAV TRAV11D TRAV12D-1 TRAV12D-1 TRAV14D-5 TRAV14D-3/DV8 TRAV14-1	TRAJ18 TRAJ22 TRAJ53 TRAJ53 TRAJ45 TRAJ32 TRAJ32 TRAJ22 TRAJ40	of oral mucosa in the ACM Day1 CDR3 CVVGDRGSALGRLHF(INKT) CALSEKSSGSWQLIF CAARNSGGSNYKLTF CALVPNTGGADRLTF CAMEDYGGSGNKLIF CAASSGSWQLIF CAASSGSWQLIF	%Reads 2.29 1.49 1.23 0.99 0.92 0.80 0.69	Rank           1           2           3           4           5           6           7	TRA Ranking Top1 TRAV TRAV11D TRAV7-5 TRAV12-2 TRAV16D/DV11 TRAV6-6 TRAV16D/DV11 TRAV1	-30 of cer TRAJ TRAJ18 TRAJ2 TRAJ37 TRAJ33 TRAJ40 TRAJ31 TRAJ33	vical lymph nodes in the ACM Day CDR3 CVVGDRGSALGRLHF(iNKT) CAMSMWRTGGLSGKLIF CALLNQGGSAKLIF CALROPGNYKYVF CALGDPGNYKYVF CAMREYNNNRVFF CANMDSNYQLIW	1 %Reads 0.22 0.06 0.06 0.06 0.05 0.04 0.04	
Rank 1 2 3 4 5 6 7 8	TRA Ranking TRAV11D TRAV11D TRAV12D-1 TRAV12D-1 TRAV13D-1 TRAV14D-3/DV8 TRAV14-1 TRAV14-1 TRAV13D-1	TRAJ18 TRAJ22 TRAJ53 TRAJ45 TRAJ45 TRAJ45 TRAJ22 TRAJ22 TRAJ40 TRAJ45	of oral mucosa in the ACM Day1 CDR3 CVVGDRGSALGRLHF(INKT) CALSEKSSCSWQLIF CAARNSCGSNYKLTF CALVPNTGGADRLTF CAMEDYGGSGNKLIF CAASSGSWQLIF CAASAGNYKYVF CAASAGNYKYVF CAMERTGGADRLTF	%Reads           2.29           1.49           1.23           0.99           0.92           0.80           0.69           0.68	Rank           1           2           3           4           5           6           7           8	TRA Ranking Top1 TRAV TRAV11D TRAV7-5 TRAV12-2 TRAV16D/DV11 TRAV6-6 TRAV16D/DV11 TRAV1 TRAV17	-30 of cer TRAJ TRAJ18 TRAJ2 TRAJ37 TRAJ33 TRAJ40 TRAJ31 TRAJ33 TRAJ50	vical lymph nodes in the ACM Day CDR3 CVVGDRCSALGRLHF(iNKT) CAMSMWRTGGLSGKLTF CALLNQGGSAKLIF CAMREGRVIW CALGDPGNYKYVF CAMREYNNRVFF CAMREYNNRVFF CAMBSNYQLIW CALETSSFSKLVF	1 %Reads 0.22 0.06 0.06 0.06 0.05 0.04 0.04 0.04	
Rank 1 2 3 4 5 6 7 8 9	TRA Ranking <b>TRAV</b> TRAV11D TRAV12D-1 TRAV10 TRAV10-1 TRAV13D-1 TRAV14-1 TRAV14-1 TRAV13D-1	Top1-30 c TRAJ TRAJ18 TRAJ22 TRAJ53 TRAJ45 TRAJ22 TRAJ22 TRAJ22 TRAJ40 TRAJ45 TRAJ45 TRAJ45	of oral mucosa in the ACM Day1 CDR3 CVVGDRGSALGRLHF(iNKT) CALSEKSSGSWQLIF CAARNSGGSNYKLTF CAALVPNTGGADRLTF CAMEDYGGSGNKLIF CAASSGSWQLIF CAASAGNYKYVF CAMERTGGADRLTF CAMEEDYAQGLTF	%Reads           2.29           1.49           1.23           0.99           0.92           0.69           0.68           0.61	Rank           1           2           3           4           5           6           7           8           9	TRA Ranking Top TRAV TRAV11D TRAV7-5 TRAV12-2 TRAV16D/DV11 TRAV6-6 TRAV16D/DV11 TRAV1 TRAV1 TRAV17 TRAV17 TRAV6D-7	-30 of cei TRAJ TRAJ18 TRAJ2 TRAJ37 TRAJ33 TRAJ40 TRAJ31 TRAJ33 TRAJ50 TRAJ33	vical lymph nodes in the ACM Day CDR3 CVVGDRGSALGRLHF(iNKT) CAMSMWRTGGLSGKLTF CALLNQGGSAKLIF CALLNQGGSAKLIF CALGDPGNYKYVF CALGDPGNYKYVF CAMREYNNNRVFF CANMDSNYQLIW CALETSSFSKLVF CALDSNYQLIW	1 %Reads 0.22 0.06 0.06 0.06 0.05 0.04 0.04 0.04 0.04	
Rank           1           2           3           4           5           6           7           8           9           10	TRA Ranking <b>TRAV</b> TRAV11D <b>TRAV12D-1</b> TRAV10 TRAV100 TRAV13D-1 TRAV14D-3/DV8 TRAV13D-1 TRAV13D-1 TRAV13D-1 TRAV13D-1 TRAV12-3	TRAJ188 TRAJ22 TRAJ333 TRAJ53 TRAJ53 TRAJ55 TRAJ32 TRAJ32 TRAJ22 TRAJ40 TRAJ45 TRAJ26 TRAJ44	of oral mucosa in the ACM Day1 CDR3 CVVGDRGSALGRLHF(iNKT) CALSEKSSGSWQLIF CAARNSGGSNYKLTF CAALVPNTGGADRLTF CAMEDYGGSGNKLIF CAASSGSWQLIF CAASAGNYKYVF CAMERTGGADRLTF CAMEEDYAQGLTF CALTAGSGGKLTL	%Reads           2.29           1.49           1.23           0.99           0.92           0.69           0.68           0.61           0.58	Rank           1           2           3           4           5           6           7           8           9           10	TRA Ranking Top TRAV TRAV11D TRAV7-5 TRAV12-2 TRAV16D/DV11 TRAV6-6 TRAV16D/DV11 TRAV1 TRAV1 TRAV17 TRAV17 TRAV60-7 TRAV14D-3/DV8	-30 of cer TRAJ TRAJ18 TRAJ2 TRAJ57 TRAJ33 TRAJ40 TRAJ31 TRAJ33 TRAJ50 TRAJ33 TRAJ58	vical lymph nodes in the ACM Day CDR3 CVVGDRGSALGRLHF(iNKT) CAMSMWRTGGLSGKLTF CALLNQGGSAKLIF CALLNQGGSAKLIF CAMREGRVIW CALGDPGNYKYVF CAMREYNNNRVFF CAMMDSNYQLIW CALETSSFSKLVF CALDSNYQLIW CAASAGTGSKLTF	1 %Reads 0.22 0.06 0.06 0.06 0.05 0.04 0.04 0.04 0.04	
Rank           1           2           3           4           5           6           7           8           9           10           11	TRA Ranking <b>TRAV11D</b> <b>TRAV12D-1</b> TRAV10 TRAV10 TRAV10 TRAV13D-1 TRAV13D-1 TRAV13D-1 TRAV13D-1 TRAV13D-1 TRAV13D-1 TRAV13D-1 TRAV12-3 TRAV6-7/DV9	TRAJ188 TRAJ22 TRAJ333 TRAJ53 TRAJ53 TRAJ55 TRAJ32 TRAJ32 TRAJ22 TRAJ40 TRAJ45 TRAJ26 TRAJ44 TRAJ53	foral mucosa in the ACM Day1 CDR3 CVVGDRCSALGRLHF(INKT) CALSEKSSGSWQLIF CAARNSGGSNYKLTF CALVPNTGGADRLTF CAMEDYGGSGNKLIF CAASSGSWQLIF CAASAGNYKYVF CAMERTGGADRLTF CAMERTGGADRLTF CAMEEDYAQGLTF CALTACSGGKLTL CALGNSGGSNYKLTF	%Reads 2.29 1.49 1.23 0.99 0.92 0.80 0.69 0.68 0.61 0.58 0.57	Rank           1           2           3           4           5           6           7           8           9           10           11	TRA Ranking Top1 TRAV TRAV11D TRAV7-5 TRAV12-2 TRAV16D/DV11 TRAV6-6 TRAV16D/DV11 TRAV1 TRAV17 TRAV17 TRAV6D-7 TRAV14D-3/DV8 TRAV9-3	-30 of cer TRAJ TRAJ18 TRAJ2 TRAJ57 TRAJ33 TRAJ40 TRAJ31 TRAJ33 TRAJ50 TRAJ33 TRAJ58 TRAJ26	vical lymph nodes in the ACM Day CDR3 CVVGDRCSALGRLHF(iNKT) CAMSMWRTGGLSGKLTF CALLNQGGSAKLIF CALLNQGGSAKLIF CAMREGRVIW CALGDPGNYKYVF CAMDSNYQLIW CALGDSNYQLIW CALGSSKLVF CALDSNYQLIW CAASAGTGSKLTF CAVRMSYAQGLTF	1 %Reads 0.22 0.06 0.06 0.06 0.05 0.04 0.04 0.04 0.04 0.04 0.04 0.04	
Rank           1           2           3           4           5           6           7           8           9           10           11           12	TRA Ranking <b>TRAV</b> TRAV11D TRAV12D-1 TRAV10 TRAV10 TRAV13D-1 TRAV14D-3/DV8 TRAV14-1 TRAV13D-1 TRAV13D-1 TRAV13D-1 TRAV13D-1 TRAV13D-1 TRAV5/DV9 TRAV4-3	Top1-30 c TRAJ TRAJ18 TRAJ22 TRAJ53 TRAJ45 TRAJ32 TRAJ22 TRAJ20 TRAJ40 TRAJ46 TRAJ44 TRAJ53 TRAJ57	of oral mucosa in the ACM Day1 CDR3 CVVGDRCSALGRLHF(INKT) CALSEKSSGSWQLIF CAARNSGGSNYKLTF CALVPNTGGADRLTF CAMEDYGGSGNKLIF CAASSGSWQLIF CAASAGNYKYVF CAMERTGGADRLTF CAMEEDYAQGLTF CALTAGSGGKLTL CALGNSGGSNYKLTF CAADGDQGGSAKLIF	%Reads           2.29           1.49           1.23           0.99           0.92           0.80           0.69           0.68           0.61           0.58           0.57           0.56	Rank           1           2           3           4           5           6           7           8           9           10           11           12	TRA Ranking Top1 TRAV TRAV11D TRAV7-5 TRAV12-2 TRAV16D/DV11 TRAV6-6 TRAV16D/DV11 TRAV6-6 TRAV16D/DV11 TRAV17 TRAV17 TRAV17 TRAV14D-3/DV8 TRAV9-3 TRAV7D-2	-30 of cer <b>TRAJ</b> <b>TRAJ18</b> <b>TRAJ2</b> <b>TRAJ33</b> <b>TRAJ33</b> <b>TRAJ33</b> <b>TRAJ33</b> <b>TRAJ33</b> <b>TRAJ33</b> <b>TRAJ50</b> <b>TRAJ35</b> <b>TRAJ26</b> <b>TRAJ35</b>	vical lymph nodes in the ACM Day CDR3 CVVGDRGSALGRLHF(iNKT) CAMSWWRTGGLSGKLIF CALLNQGGSAKLIF CALLNQGGSAKLIF CALGPCNYKYVF CALGDFCNYKYVF CAMDSNYQLIW CALETSSFSKLVF CALDSNYQLIW CALSNYQLIW CAASAGTGSKLIF CAVRKSYAQGLIF CAARFVSALTF	1 %Reads 0.22 0.06 0.06 0.06 0.06 0.05 0.04 0.04 0.04 0.04 0.04 0.04 0.04	
Rank           1           2           3           4           5           6           7           8           9           10           11           12           13	TRA Ranking TRAV11D TRAV11D TRAV12D-1 TRAV12D-1 TRAV13D-1 TRAV13D-1 TRAV13D-1 TRAV13D-1 TRAV13D-1 TRAV13D-1 TRAV13D-1 TRAV43 TRAV4-3 TRAV6-3 TRAV9-3	Top1-30 c TRAJ TRAJ18 TRAJ22 TRAJ53 TRAJ45 TRAJ45 TRAJ20 TRAJ40 TRAJ46 TRAJ44 TRAJ53 TRAJ57 TRAJ44	of oral mucosa in the ACM Day1 CDR3 CVVGDRGSALGRLHF(INKT) CALSEKSSCSWQLIF CAARNSGGSNYKLIF CALVPNTGGADRLTF CAMEDYGGSGNKLIF CAASSGSWQLIF CAASAGNYKYVF CAMERTGGADRLTF CAMEEDYAQGLTF CALAGSGGSLTL CALGNSGGSNYKLTF CAADGDQGCSAKLIF CAADGDQGCSAKLIF	**************************************	Rank 1 2 3 4 5 6 7 8 9 10 11 12 13	TRA Ranking Topi TRAV TRAV11D TRAV7-5 TRAV16D/DV11 TRAV6-6 TRAV16D/DV11 TRAV6-6 TRAV16D/DV11 TRAV17 TRAV17 TRAV17 TRAV14D-3/DV8 TRAV9-3 TRAV7D-2 TRAV6-7/DV9	-30 of cer TRAJ18 TRAJ18 TRAJ2 TRAJ27 TRAJ33 TRAJ40 TRAJ31 TRAJ33 TRAJ50 TRAJ33 TRAJ58 TRAJ26 TRAJ35 TRAJ27	vical lymph nodes in the ACM Day CDR3 CVVGDRGSALGRLHF(iNKT) CAMSWWRTGCLSGKLIF CALLNQGGSAKLIF CALLNQGGSAKLIF CALGPCNYKYVF CALGDCNYKYVF CAMREYNNNRVFF CANDSNYQLIW CALETSSFSKLVF CALDSNYQLIW CAASAGTGSKLIF CAVRMSYAQGLIF CAARFVSALIF CAARFVSALIF CALAYNINTGKLIF	1 %Reads 0.22 0.06 0.06 0.06 0.06 0.05 0.04 0.04 0.04 0.04 0.04 0.04 0.03 0.03	
Rank 1 2 3 4 5 6 7 8 9 10 11 12 13 14	TRA Ranking           TRAV11D           TRAV11D           TRAV11D           TRAV12D-1           TRAV10           TRAV10           TRAV10           TRAV10           TRAV10           TRAV10-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV12-3           TRAV6-7/DV9           TRAV4-3           TRAV9-3           TRAV4D-3	Top1-30 c TRAJ TRAJ18 TRAJ22 TRAJ53 TRAJ53 TRAJ45 TRAJ22 TRAJ40 TRAJ44 TRAJ44 TRAJ44 TRAJ53 TRAJ44 TRAJ57	of oral mucosa in the ACM Day1 CDR3 CVVGDRGSALGRLHF(INKT) CALSEKSSCSWQLIF CAARNSGGSNYKLTF CALVPNTGGADRLTF CAADYGGSGNKLIF CAASSGSWQLIF CAASAGNYKYVF CAMERTGGADRLTF CAMEEDYAQGLTF CAMEEDYAQGLTF CALTAGSGGKLTL CALGNSGGSNYKLTF CAADGDQGGSAKLIF CAVFTGSGGKLTL CAADGDQGCSAKLIF	%Reads           2.29           1.49           1.23           0.99           0.92           0.80           0.69           0.68           0.61           0.58           0.57           0.56           0.54           0.53	Rank 1 2 3 4 5 6 7 8 9 10 11 12 13 14	TRA Ranking Top1 TRAV TRAV11D TRAV7-5 TRAV16D/DV11 TRAV6-6 TRAV16D/DV11 TRAV6- TRAV17 TRAV17 TRAV6D-7 TRAV4D-3/DV8 TRAV9-3 TRAV7D-2 TRAV6D-3	-30 of cer TRAJ1 TRAJ18 TRAJ2 TRAJ37 TRAJ33 TRAJ40 TRAJ31 TRAJ33 TRAJ50 TRAJ33 TRAJ58 TRAJ26 TRAJ27 TRAJ31	vical lymph nodes in the ACM Day CDR3 CVVGDRGSALGRLHF(iNKT) CAMSWWRTGGLSGKLTF CALLNQGGSAKLIF CAMREGRVIW CALGDPGNYKYVF CAMREYNNNRVFF CAMREYNNNRVFF CAMDSNYQLIW CALETSSFSKLVF CALDSNYQLIW CALASAGTGSKLTF CAVRMSYAQGLTF CAARFVSALTF CALANTNTGKLTF CALANTNTGKLTF	1 %Reads 0.22 0.06 0.06 0.06 0.05 0.04 0.05 0.04 0.04 0.04 0.04 0.04	
Rank 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	TRA Ranking           TRAV11D           TRAV12D-1           TRAV12D-1           TRAV10           TRAV13D-1           TRAV14-3           TRAV4-3           TRAV4-3           TRAV4-3           TRAV5-3	Top1-30 c TRAJ TRAJ18 TRAJ22 TRAJ53 TRAJ53 TRAJ52 TRAJ22 TRAJ40 TRAJ46 TRAJ46 TRAJ46 TRAJ57 TRAJ57 TRAJ7	of oral mucosa in the ACM Day1 CDR3 CVVGDRGSALGRLHF(INKT) CALSEKSSCSWQLIF CAARNSGGSNYKLIF CALVPNTGGADRLTF CALVPNTGGADRLTF CAABCYGGSGNKLIF CAASSGSWQLIF CAASSGSWQLIF CAABCGADRLTF CAMEEDYAQGLTF CALTACSGGKLTL CALGNSGGSNYKLTF CAADGDQGGSAKLIF CAADGDQGCSAKLIF CAADGDQGCSAKLIF CAADGDQGCSAKLIF CSASKGYSNNRLTL	%Reads           2.29           1.49           1.23           0.99           0.80           0.69           0.68           0.61           0.58           0.57           0.54           0.53           0.52	Rank 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	TRA Ranking Top1           TRAV           TRAV11D           TRAV7-5           TRAV12-2           TRAV16D/DV11           TRAV14D-3/DV8           TRAV6D-3           TRAV14D-3/DV8	-30 of cer TRAJ18 TRAJ18 TRAJ2 TRAJ37 TRAJ33 TRAJ40 TRAJ31 TRAJ33 TRAJ50 TRAJ33 TRAJ58 TRAJ26 TRAJ35 TRAJ21 TRAJ31 TRAJ22	vical lymph nodes in the ACM Day CDR3 CVVGDRCSALGRLHF(iNKT) CAMSMWRTGGLSGKLTF CALLNQGGSAKLIF CAMREGRVIW CALGDPGNYKYVF CANGPNYRVFF CANMDSNYQLIW CALETSSFSKLVF CALDSNYQLIW CAASAGTGSKLTF CAVRMSYAQGLTF CAARFVSALTF CALAYNTNTGKLTF CALAYNTNTGKLTF CAMRDRHNNNRIFF CAASSDSWQLIF	1 %Reads 0.22 0.06 0.06 0.06 0.06 0.06 0.04 0.04 0.04	
Rank 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	TRA Ranking           TRAV1           TRAV11D           TRAV11D           TRAV10           TRAV10           TRAV13D-1           TRAV141-           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV12-3           TRAV4-3           TRAV9-3           TRAV9-3           TRAV5-1           TRAV5-1	TRAJ3 TRAJ3 TRAJ3 TRAJ3 TRAJ3 TRAJ32 TRAJ32 TRAJ32 TRAJ45 TRAJ40 TRAJ46 TRAJ46 TRAJ45 TRAJ44 TRAJ57 TRAJ44 TRAJ57 TRAJ7 TRAJ7 TRAJ7	foral mucosa in the ACM Day1 CDR3 CVVGDRCSALGRLHF(iNKT) CALSEKSSGSWQLIF CAARNSGGSNYKLTF CALVPNTGGADRLTF CAAVPNTGGADRLTF CAASAGNYKYVF CAMERTGGADRLTF CAMERTGGADRLTF CAMERTGGADRLTF CALTACSGGKLTL CALGNSGGSNYKLTF CAAGDQGGSAKLIF CAAGDQGGSAKLIF CAVFTCSGGKLTL CAAGDQGGSAKLIF CSASKGYSNNRLTL CAALTGGADRLTF	%Reads           2.29           1.49           1.23           0.99           0.92           0.80           0.69           0.68           0.61           0.58           0.57           0.56           0.54           0.53           0.52	Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16	TRA Ranking Top1           TRAV           TRAV11D           TRAV7-5           TRAV12-2           TRAV16D/DV11           TRAV6-6           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV17           TRAV17           TRAV170-2           TRAV7D-2           TRAV6-7/DV9           TRAV6D-3           TRAV12-3	-30 of cer TRAJ TRAJ18 TRAJ2 TRAJ57 TRAJ33 TRAJ40 TRAJ33 TRAJ50 TRAJ33 TRAJ56 TRAJ26 TRAJ35 TRAJ27 TRAJ21 TRAJ21 TRAJ21	vical lymph nodes in the ACM Day CDR3 CVVGDRCSALGRLHF(iNKT) CAMSMWRTGGLSGKLTF CALLNQGGSAKLIF CALLNQGGSAKLIF CALGDPGNYKYVF CALGDPGNYKYVF CALGDSNYQLIW CALETSSFSKLVF CALDSNYQLIW CALETSSFSKLVF CALDSNYQLIW CAASAGTGSKLTF CAVRMSYAQGLTF CAARFVSALTF CALAYNTNTGKLTF CALAYNTNTGKLTF CAASSDSWQLIF CAASSDSWQLIF CAASSDSWQLIF	1 %Reads 0.22 0.06 0.06 0.06 0.06 0.05 0.04 0.04 0.04 0.04 0.04 0.04 0.04	
Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17	TRA Ranking           TRAV11D           TRAV11D           TRAV11D           TRAV10           TRAV10           TRAV10           TRAV10           TRAV13D-1           TRAV14D-3/DV8           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV14-3           TRAV4-3           TRAV9-3           TRAV9-3           TRAV5-1           TRAV4-5           TRAV5-1           TRAV5-1	TRAJ18 TRAJ18 TRAJ22 TRAJ22 TRAJ23 TRAJ45 TRAJ45 TRAJ45 TRAJ40 TRAJ45 TRAJ44 TRAJ53 TRAJ57 TRAJ44 TRAJ7 TRAJ7 TRAJ7 TRAJ44	of oral mucosa in the ACM Day1 CDR3 CVVGDRCSALGRLHF(INKT) CALSEKSSGSWQLIF CAARNSGGSNYKLTF CALVPNTGGADRLTF CAMEDYGGSGNKLIF CAASAGNYKYVF CAMERTGGADRLTF CAASAGGKUTL CALGNSGGSNYKLTF CAAGGDQGGSAKLIF CAAGDQQGGSAKLIF CAAGDQQGGSAKLIF CAAGDQQGGSAKLIF CSASKGYSNNRLTL CAALTGGADRLTF CAALTGGADRLTF CAPNTGNYKYVF	%Reads           2.29           1.49           1.23           0.99           0.61           0.68           0.61           0.53           0.52           0.52           0.52           0.52           0.52           0.52           0.51	Rank 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	TRA Ranking Top1           TRAV11D           TRAV11D           TRAV7-5           TRAV1022           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV9-3           TRAV7-5           TRAV7-7           TRAV6D-7           TRAV70-2           TRAV6-7/DV9           TRAV60-3           TRAV12-3           TRAV12-3	-30 of cer TRAJ TRAJ18 TRAJ2 TRAJ37 TRAJ33 TRAJ40 TRAJ33 TRAJ40 TRAJ33 TRAJ50 TRAJ35 TRAJ26 TRAJ35 TRAJ27 TRAJ21 TRAJ22 TRAJ50 TRAJ20	vical lymph nodes in the ACM Day CDR3 CVVGDRGSALGRLHF(iNKT) CAMSWWRTGGLSGKLTF CALLNQGGSAKLIF CALLNQGGSAKLIF CAMREGRVIW CALGDPGNYKYVF CAMDSNYQLIW CALGDSNYQLIW CAASAGTGSKLTF CAALDSNYQLIW CAASAGTGSKLTF CAARFVSALTF CAARFVSALTF CALAYNTNTGKLTF CAARSSDSWQLIF CAASSSDSWQLIF CALRIASSSFSKLVF CALRIASSSFSKLVF	1 %Reads 0.22 0.06 0.06 0.06 0.06 0.06 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.03 0.03 0.03 0.03 0.03 0.03 0.03	
Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18	TRA Ranking           TRAV11D           TRAV11D           TRAV11D           TRAV10           TRAV10           TRAV10           TRAV13D-1           TRAV14D-3/DV8           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV12-3           TRAV742-3           TRAV6-7/DV9           TRAV5-1           TRAV5-1           TRAV5-1           TRAV5-1           TRAV5-1	TRAJ18 TRAJ18 TRAJ22 TRAJ23 TRAJ53 TRAJ53 TRAJ52 TRAJ22 TRAJ22 TRAJ40 TRAJ45 TRAJ46 TRAJ53 TRAJ57 TRAJ44 TRAJ57 TRAJ44 TRAJ57 TRAJ40 TRAJ40 TRAJ40 TRAJ40 TRAJ45	of oral mucosa in the ACM Day1 CDR3 CVVGDRCSALGRLHF(INKT) CALSEKSSGSWQLIF CAARNSGGSNYKLTF CALVPNTGGADRLTF CAMEDYGGSGNKLIF CAASSGSWQLIF CAASAGNYKYVF CAMERTGGADRLTF CAMEEDYAQGLTF CALTAGSGGKLTL CALGSGGSNYKLTF CAAGDQQGGSAKLIF CAAGDQQGGSAKLIF CAAGDQQGGSAKLIF CSASKGYSNNRLTL CAALTGGADRLTF CAPNTGNYKYVF CSASPGGYKVVF	%Reads           2.29           1.49           1.23           0.99           0.92           0.80           0.69           0.68           0.61           0.58           0.57           0.56           0.54           0.52           0.51           0.50	Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18	TRA Ranking Top1           TRAV           TRAV11D           TRAV7-5           TRAV12-2           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV10-7           TRAV6D-7           TRAV6D-7           TRAV7-2           TRAV6-3           TRAV60-3           TRAV14D-3/DV8           TRAV12-3           TRAV4-3	-30 of cer TRAJ18 TRAJ18 TRAJ2 TRAJ37 TRAJ30 TRAJ40 TRAJ31 TRAJ30 TRAJ50 TRAJ35 TRAJ26 TRAJ35 TRAJ27 TRAJ21 TRAJ22 TRAJ50 TRAJ27 TRAJ57	vical lymph nodes in the ACM Day CDR3 CVVGDRGSALGRLHF(iNKT) CAMSWWRTGGLSGKLTF CALLNQGGSAKLIF CALLNQGGSAKLIF CALDPCNYKYVF CALDPCNYKYVF CALDSNYQLIW CALETSSFSKLVF CALDSNYQLIW CALETSSFSKLVF CALDSNYQLIW CAASAGTGSKLTF CAARFVSALTF CAARFVSALTF CALAYNTNTGKLTF CALAYNTNTGKLTF CALASSSDSWQLIF CALRASSSFSKLVF CALRASSEFSKLVF CALRASSEFSKLVF CATEPGTNTGKLTF	1 %Reads 0.22 0.06 0.06 0.06 0.06 0.05 0.04 0.04 0.04 0.04 0.04 0.04 0.04	
Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19	TRA Ranking           TRAV           TRAV11D           TRAV12D-1           TRAV13D-1           TRAV4-1           TRAV5-1           TRAV5-1           TRAV5-1           TRAV4-4/DV10           TRAV5-1           TRAV5-1           TRAV5-1           TRAV5-1	Top1-30 c           TRAJ           TRAJ18           TRAJ22           TRAJ53           TRAJ54           TRAJ22           TRAJ22           TRAJ32           TRAJ33           TRAJ40           TRAJ45           TRAJ6           TRAJ64           TRAJ7           TRAJ8           TRAJ97           TRAJ32           TRAJ32           TRAJ44           TRAJ7           TRAJ45           TRAJ41           TRAJ57           TRAJ41           TRAJ57           TRAJ41           TRAJ41           TRAJ42           TRAJ43	of oral mucosa in the ACM Day1 CDR3 CVVGDRGSALGRLHF(INKT) CALSEKSSGSWQLIF CAARNSGGSNYKLTF CALVPNTGGADRLTF CAMEDYGCSGNKLIF CAASSGSWQLIF CAASSGSWQLIF CAAGDYGCGSAKLIF CALTAGSGGKLTL CALTAGSGGKLTL CAAGDQGCSAKLIF CAADGDQGCSAKLIF CAADGDQGCSAKLIF CAADGDQGCSAKLIF CSASKGYSNNRLTL CAALTGGADRLTF CAAPNTGNYKYVF CSASPGGYKVVF CALSAPDAYKVIF	%Reads           2.29           1.49           1.23           0.99           0.92           0.80           0.69           0.68           0.61           0.56           0.57           0.56           0.54           0.52           0.52           0.51           0.50           0.49	Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19	TRA Ranking Top1           TRAV           TRAV11D           TRAV7-5           TRAV102           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV17           TRAV16D/DV11           TRAV16D/DV11           TRAV17           TRAV6D-7           TRAV6D-7           TRAV5-3           TRAV5-3           TRAV6-7/DV9           TRAV14D-3/DV8           TRAV12-3           TRAV2-3           TRAV4-3           TRAV4-3	-30 of cer TRAJ TRAJ18 TRAJ2 TRAJ2 TRAJ30 TRAJ30 TRAJ31 TRAJ33 TRAJ30 TRAJ35 TRAJ35 TRAJ26 TRAJ35 TRAJ27 TRAJ21 TRAJ27 TRAJ27 TRAJ32	vical lymph nodes in the ACM Day CDR3 CVVGDRGSALGRLHF(iNKT) CAMSWWRTGCLSGKLTF CALLNQGGSAKLIF CALLNQGGSAKLIF CALGPCNYKYVF CALGDCNYKYVF CALGDCNYKYVF CALGSNYQLIW CALETSSFSKLVF CALGSNYQLIW CAASAGTGSKLTF CALGSKLTF CALASYAQGLTF CAARFVSALTF CALAYNTNTGKLTF CALAYNTNTGKLTF CALAYNTNTGKLTF CALAYNTNTGKLTF CALAYNTNTGKLTF CAASSSDSWQLIF CALIASSSFSKLVF CATEPGTNTGKLTF CAAGEQGSAKLIF	1 %Reads 0.22 0.06 0.06 0.06 0.06 0.05 0.04 0.04 0.04 0.04 0.04 0.04 0.03 0.03	
Rank 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	TRA Ranking           TRAV11D           TRAV11D           TRAV11D           TRAV12D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV4-3           TRAV5-7/DV9           TRAV5-1	Top1-30 c           TRAJ           TRAJ18           TRAJ22           TRAJ332           TRAJ32           TRAJ32           TRAJ32           TRAJ32           TRAJ40           TRAJ53           TRAJ44           TRAJ53           TRAJ44           TRAJ7           TRAJ44           TRAJ7           TRAJ40           TRAJ7           TRAJ40           TRAJ7           TRAJ40           TRAJ40           TRAJ40           TRAJ40           TRAJ40           TRAJ40           TRAJ40           TRAJ40	of oral mucosa in the ACM Day1 CDR3 CVVGDRGSALGRLHF(INKT) CALSEKSSCSWQLIF CAARNSGGSNYKLTF CALVPNTGGADRLTF CALVPNTGGADRLTF CAABDYGCSGNKLIF CAASSGSWQLIF CAAGAGDYAQGLTF CAMEEDYAQGLTF CALAGSGGSNYKLTF CALAGSGGSNYKLTF CAADGDQGCSAKLIF CAADGDQGCSAKLIF CAADGDQGCSAKLIF CAADGDQGCSAKLIF CAADGDQGCSAKLIF CSASKGYSNNRLTL CAALTGGADRLTF CAPNTGNYKYVF CSASPGGYKVVF CALSAPDAYKVIF CALNNNAPRF	%Reads           2.29           1.49           1.23           0.99           0.92           0.80           0.69           0.68           0.61           0.57           0.56           0.54           0.53           0.52           0.51           0.50           0.49           0.49           0.48	Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19           20	TRA Ranking Top1           TRAV           TRAV11D           TRAV7-5           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV10-7           TRAV5-7           TRAV60-7           TRAV60-7           TRAV60-7           TRAV5-2           TRAV60-3/DV8           TRAV14D-3/DV8           TRAV12-3           TRAV12-3           TRAV12-3           TRAV4-3           TRAV13D-1	-30 of cer TRAJ TRAJ18 TRAJ2 TRAJ37 TRAJ30 TRAJ33 TRAJ30 TRAJ33 TRAJ50 TRAJ33 TRAJ26 TRAJ27 TRAJ21 TRAJ22 TRAJ57 TRAJ27 TRAJ27 TRAJ27 TRAJ22 TRAJ27	vical lymph nodes in the ACM Day CDR3 CVVGDRGSALGRLHF(iNKT) CAMSWWRTGCLSGKLIF CALLNQGGSAKLIF CALLNQGGSAKLIF CALGPCNYKYVF CALGDCNYKYVF CALGDCNYKYVF CALGDCNYKYVF CALGSNYQLIW CALETSSFSKLVF CALGSNYQLIW CAASAGTGSKLIF CAARFVSALIF CAARFVSALIF CAARFVSALIF CAARFVSALIF CAARFVSALIF CAARFVSALIF CAARFVSALIF CAARSSDSWQLIF CALRIASSSFSKLVF CATEPGTNTGKLIF CAAGEQGGSAKLIF CAABCGGGSAKLIF CAARLSGSFNKKLIF	1 %Reads 0.22 0.06 0.06 0.06 0.05 0.04 0.04 0.04 0.04 0.04 0.04 0.03 0.03	
Rank 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	TRA Ranking           TRAVI           TRAV11D           TRAV11D           TRAV12D-1           TRAV10           TRAV13D-1           TRAV13D-1           TRAV14D-3/DV8           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV12-3           TRAV6-7/DV9           TRAV4-3           TRAV9-3           TRAV5-1           TRAV5-1           TRAV5-1           TRAV5-1           TRAV5-1           TRAV5-1           TRAV5-1           TRAV12-3           TRAV2-3           TRAV2-3	Top1-30 c           TRAJ           TRAJ8           TRAJ33           TRAJ53           TRAJ53           TRAJ54           TRAJ55           TRAJ22           TRAJ33           TRAJ45           TRAJ46           TRAJ53           TRAJ46           TRAJ47           TRAJ57           TRAJ44           TRAJ57           TRAJ57           TRAJ44           TRAJ57           TRAJ45           TRAJ40           TRAJ40           TRAJ30           TRAJ31           TRAJ33	of oral mucosa in the ACM Day1 CDR3 CVVGDRGSALGRLHF(INKT) CALSEKSSCSWQLIF CAARNSGGSNYKLTF CAARNSGGSNYKLTF CALVPNTGGADRLTF CAADYGGSGNKLIF CAASSGSWQLIF CAASAGNYKYVF CAMERTGGADRLTF CAMEEDYAQGLTF CAALTAGSGGKLTL CAAGDQGGSAKLIF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CSASKGYSNNRLTL CAADGDQGCSAKLIF CSASKGYSNNRLTL CAALTGGADRLTF CAALTGGADRLTF CAALTGGADRLTF CAALTGGADRLTF CAALTGGADRLTF CALNNNAPRF CALNNNAPRF	%Reads           2.29           1.49           1.23           0.99           0.92           0.80           0.69           0.68           0.61           0.58           0.57           0.56           0.54           0.52           0.52           0.51           0.50           0.49           0.48           0.48	Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19           20           20           21	TRA Ranking Top1           TRAV           TRAV11D           TRAV7-5           TRAV12-2           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/JV11           TRAV16D/JV11           TRAV16D/JV11           TRAV50-7           TRAV6D-7           TRAV60-7           TRAV60-3           TRAV6-7/DV9           TRAV6-3/DV8           TRAV14D-3/DV8           TRAV12-3           TRAV12-3           TRAV8-2           TRAV4-3           TRAV13D-1           TRAV7D-2	-30 of cer TRAJ1 TRAJ18 TRAJ2 TRAJ57 TRAJ33 TRAJ33 TRAJ33 TRAJ50 TRAJ33 TRAJ50 TRAJ35 TRAJ26 TRAJ27 TRAJ21 TRAJ27 TRAJ57 TRAJ27 TRAJ77 TRAJ77 TRAJ77 TRAJ77 TRAJ77 TRAJ77 TRAJ77 TRA TRA TRA TRA TRA TRA TRA TRA	vical lymph nodes in the ACM Day CDR3 CVVGDRGSALGRLHF(iNKT) CAMSMWRTGGLSGKLIF CALLNQGGSAKLIF CALLNQGGSAKLIF CALGPGNYKYVF CALGDPGNYKYVF CALGPGNYKYVF CALGPSTSKLVF CALMSNYQLIW CALETSSFSKLVF CALDSNYQLIW CALSSTSKLTF CAVRMSYAQGLTF CALASAGTGSKLTF CALANTNTGKLTF CALANTNTGKLTF CALASSFSKLVF CALARFVSALTF CALANTNTGKLTF CALASSFSKLVF CALFPCTNTGKLTF CAARGEQGGSAKLIF CAMEDYGGRGNKLIF CAARLSGSFNKMTF CALSSFNKMTF	1 %Reads 0.22 0.06 0.06 0.06 0.05 0.04 0.05 0.04 0.04 0.04 0.04 0.04	
Rank 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	TRA Ranking           TRAV1D           TRAV1D           TRAV1D           TRAV1D           TRAV10           TRAV13D-1           TRAV13D-1           TRAV14D-3/DV8           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV5-1           TRAV5-7/DV9           TRAV5-3           TRAV5-1           TRAV5-1           TRAV5-1           TRAV12-2           TRAV12-3           TRAV12-3           TRAV12-3           TRAV12-3	Topl-30 c           TRAJ           TRAJ18           TRAJ22           TRAJ33           TRAJ33           TRAJ32           TRAJ32           TRAJ33           TRAJ45           TRAJ46           TRAJ53           TRAJ44           TRAJ57           TRAJ45           TRAJ46           TRAJ57           TRAJ45           TRAJ46           TRAJ57           TRAJ41           TRAJ57           TRAJ40           TRAJ57           TRAJ41           TRAJ42           TRAJ43           TRAJ43           TRAJ43           TRAJ43           TRAJ43           TRAJ44	of oral mucosa in the ACM Day1 CDR3 CVVGDRCSALGRLHF(INKT) CALSEKSSGSWQLIF CAARNSGGSNYKLTF CALVPNTGGADRLTF CAMEDYGGSGNKLIF CAASSGSWQLIF CAASAGNYKYVF CAMERTGGADRLTF CAMERTGGADRLTF CAMERTGGADRLTF CAMERTGGADRLTF CAMERTGGADRLTF CAAGDQGGSAKLIF CAALTACSGGKLTL CAAGDQGGSAKLIF CAAJGDQGGSAKLIF CAASGQNYKVF CSASKGYSNNRLTL CAALTGGADRLTF CAPNTGNYKVF CSASPGGYKVVF CALSAPDAYKVIF CALSARVGDNSKLIW CAALSGRNVGDNSKLIW	%Reads           2.29           1.49           1.23           0.99           0.61           0.58           0.57           0.56           0.54           0.55           0.52           0.51           0.52           0.51           0.52           0.53           0.49           0.48           0.48           0.48	Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19           20           21           22	TRA Ranking Top1           TRAV11D           TRAV11D           TRAV175           TRAV122           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV17           TRAV16D/J0V11           TRAV6-6           TRAV17D           TRAV60-7           TRAV6-7/DV9           TRAV6-7/DV9           TRAV6-7/DV9           TRAV6-3           TRAV12-3           TRAV12-3           TRAV8-2           TRAV13D-1           TRAV13D-2           TRAV13D-2           TRAV14D-3/DV8	-30 of cer TRAJ TRAJ18 TRAJ2 TRAJ37 TRAJ33 TRAJ33 TRAJ33 TRAJ33 TRAJ33 TRAJ26 TRAJ35 TRAJ27 TRAJ22 TRAJ22 TRAJ22 TRAJ27 TRAJ37 TRAJ22 TRAJ37 TRAJ37 TRAJ23	vical lymph nodes in the ACM Day CDR3 CVVGDRCSALGRLHF(iNKT) CAMSMWRTGGLSGKLTF CALLNQGGSAKLIF CALLNQGGSAKLIF CALGDPGNYKYVF CALGDPGNYKYVF CALGDPGNYKVF CALGDSNYQLIW CALETSSFSKLVF CALSNYQLIW CASAGTGSKLTF CAVRMSYAQGLTF CAASAGTGSKLTF CALAYNTNTGKLTF CALAYNTNTGKLTF CALAYNTNTGKLTF CALASSDSWQLIF CALRIASSSFSKLVF CATEPGTNTGKLTF CAASSDSWQLIF CAARSSSFSKLVF CATEPGTNTGKLTF CAAGGEQGGSAKLIF CAAGGEQGGSAKLIF CAALSGFNKMTF CAALSGSFNKMTF CALSUS	1 %Reads 0.22 0.06 0.06 0.06 0.06 0.05 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.03 0	
Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19           20           21           22           23	TRA Ranking           TRAV11D           TRAV11D           TRAV11D           TRAV10           TRAV10           TRAV10           TRAV10           TRAV10           TRAV10           TRAV13D-1           TRAV14D-3/DV8           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV4-3           TRAV9-3           TRAV9-3           TRAV9-3           TRAV5-1           TRAV5-1           TRAV5-1           TRAV5-1           TRAV5-1           TRAV12-3           TRAV3-3           TRAV3-3           TRAV3-3 <td>Topl-30 c           TRAJ           TRAJ18           TRAJ22           TRAJ32           TRAJ32           TRAJ45           TRAJ32           TRAJ32           TRAJ45           TRAJ33           TRAJ44           TRAJ53           TRAJ44           TRAJ55           TRAJ45           TRAJ46           TRAJ57           TRAJ47           TRAJ57           TRAJ44           TRAJ57           TRAJ40           TRAJ54           TRAJ54           TRAJ55           TRAJ64           TRAJ54           T</td> <td>of oral mucosa in the ACM Day1 CDR3 CVVGDRCSALGRLHF(INKT) CALSEKSSGSWQLIF CAARNSGGSNYKLTF CALVPNTGGADRLTF CAMEDYGGSGNKLIF CAASSGSWQLIF CAASAGNYKYVF CAMERTGGADRLTF CAASAGGNYKUF CALTAGSGGKLTL CALGNSGGSNYKLTF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CAAJGDQGGSAKLIF CAAJGDQGGSAKLIF CAAJGDQGGSAKLIF CAAJGDQGGSAKLIF CAAJGDQGGSAKLIF CAAJGDQGGSAKLIF CAAJGDQGGSAKLIF CAAJGDQGGSAKLIF CAAJGDQGGSAKLIF CAAJGDQGGSAKLIF CALTAGADRLTF CALSAPDAYKVIF CALSAPDAYKVIF CALSGRNVGDNSKLIW CAVSAGGADRLTF CAVSHYAQGLTF</td> <td>%Reads           2.29           1.49           1.23           0.99           0.61           0.68           0.61           0.58           0.57           0.56           0.54           0.52           0.51           0.50           0.49           0.48           0.48           0.46</td> <td>Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19           20           21           22           23</td> <td>TRA Ranking Top1           TRAV11D           TRAV11D           TRAV11D           TRAV122           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV17           TRAV000000000000000000000000000000000000</td> <td>-30 of cer TRAJ1 TRAJ18 TRAJ2 TRAJ33 TRAJ30 TRAJ33 TRAJ40 TRAJ33 TRAJ50 TRAJ33 TRAJ50 TRAJ26 TRAJ35 TRAJ27 TRAJ27 TRAJ27 TRAJ27 TRAJ57 TRAJ27</td> <td>vical lymph nodes in the ACM Day CDR3 CVVGDRGSALGRLHF(iNKT) CAMSWWRTGGLSGKLTF CALLNQGGSAKLIF CALLNQGGSAKLIF CAMREGRVIW CALGDPGNYKYVF CAMDSNYQLIW CALGDPGNYKYVF CAMDSNYQLIW CALGSNYQLIW CAASAGTGSKLTF CAASSY CAASAGTGSKLTF CAASST CAARFVSALTF CALAYNTNTGKLTF CALAYNTNTGKLTF CALAYNTNTGKLTF CAASSSSWQLIF CAARFCSALF CAAGGEQGGSAKLIF CAAGGEQGGSAKLIF CAARSGSWQLIF CAASST CAASSOSWQLIF CAASST CAASSOSWQLIF CAASST CAASSOSWQLIF CAASSOSWQLIF CAASSOSWQLIF CAASSOSWQLIF CAASSWTGANTGKLTF</td> <td>1 %Reads 0.22 0.06 0.06 0.06 0.06 0.06 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.03 0</td>	Topl-30 c           TRAJ           TRAJ18           TRAJ22           TRAJ32           TRAJ32           TRAJ45           TRAJ32           TRAJ32           TRAJ45           TRAJ33           TRAJ44           TRAJ53           TRAJ44           TRAJ55           TRAJ45           TRAJ46           TRAJ57           TRAJ47           TRAJ57           TRAJ44           TRAJ57           TRAJ40           TRAJ54           TRAJ54           TRAJ55           TRAJ64           TRAJ54           T	of oral mucosa in the ACM Day1 CDR3 CVVGDRCSALGRLHF(INKT) CALSEKSSGSWQLIF CAARNSGGSNYKLTF CALVPNTGGADRLTF CAMEDYGGSGNKLIF CAASSGSWQLIF CAASAGNYKYVF CAMERTGGADRLTF CAASAGGNYKUF CALTAGSGGKLTL CALGNSGGSNYKLTF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CAAJGDQGGSAKLIF CAAJGDQGGSAKLIF CAAJGDQGGSAKLIF CAAJGDQGGSAKLIF CAAJGDQGGSAKLIF CAAJGDQGGSAKLIF CAAJGDQGGSAKLIF CAAJGDQGGSAKLIF CAAJGDQGGSAKLIF CAAJGDQGGSAKLIF CALTAGADRLTF CALSAPDAYKVIF CALSAPDAYKVIF CALSGRNVGDNSKLIW CAVSAGGADRLTF CAVSHYAQGLTF	%Reads           2.29           1.49           1.23           0.99           0.61           0.68           0.61           0.58           0.57           0.56           0.54           0.52           0.51           0.50           0.49           0.48           0.48           0.46	Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19           20           21           22           23	TRA Ranking Top1           TRAV11D           TRAV11D           TRAV11D           TRAV122           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV17           TRAV000000000000000000000000000000000000	-30 of cer TRAJ1 TRAJ18 TRAJ2 TRAJ33 TRAJ30 TRAJ33 TRAJ40 TRAJ33 TRAJ50 TRAJ33 TRAJ50 TRAJ26 TRAJ35 TRAJ27 TRAJ27 TRAJ27 TRAJ27 TRAJ57 TRAJ27	vical lymph nodes in the ACM Day CDR3 CVVGDRGSALGRLHF(iNKT) CAMSWWRTGGLSGKLTF CALLNQGGSAKLIF CALLNQGGSAKLIF CAMREGRVIW CALGDPGNYKYVF CAMDSNYQLIW CALGDPGNYKYVF CAMDSNYQLIW CALGSNYQLIW CAASAGTGSKLTF CAASSY CAASAGTGSKLTF CAASST CAARFVSALTF CALAYNTNTGKLTF CALAYNTNTGKLTF CALAYNTNTGKLTF CAASSSSWQLIF CAARFCSALF CAAGGEQGGSAKLIF CAAGGEQGGSAKLIF CAARSGSWQLIF CAASST CAASSOSWQLIF CAASST CAASSOSWQLIF CAASST CAASSOSWQLIF CAASSOSWQLIF CAASSOSWQLIF CAASSOSWQLIF CAASSWTGANTGKLTF	1 %Reads 0.22 0.06 0.06 0.06 0.06 0.06 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.03 0	
Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19           20           21           22           23           24	TRA Ranking           TRAV11D           TRAV11D           TRAV11D           TRAV11D           TRAV10           TRAV10           TRAV10           TRAV10           TRAV13D-1           TRAV14D-3/DV8           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV70-3           TRAV51           TRAV5-1           TRAV5-1           TRAV5-1           TRAV5-1           TRAV5-1           TRAV12-3           TRAV5-1           TRAV5-1           TRAV12-3           TRAV9-3           TRAV9-3           TRAV9-3           TRAV9-3           TRAV12-3	Topl-30 c           TRAJ           TRAJ18           TRAJ22           TRAJ33           TRAJ53           TRAJ22           TRAJ32           TRAJ33           TRAJ45           TRAJ53           TRAJ44           TRAJ53           TRAJ44           TRAJ57           TRAJ44           TRAJ57           TRAJ40           TRAJ40           TRAJ40           TRAJ40           TRAJ50           TRAJ41           TRAJ51           TRAJ51           TRAJ51           TRAJ51           TRAJ41           TRAJ51           TRAJ51           TRAJ51           TRAJ51           TRAJ51           TRAJ51           TRAJ51           TRAJ51           TRAJ53           TRAJ30           TRAJ31           TRAJ33           TRAJ44           TRAJ53           TRAJ45           TRAJ45           TRAJ46           TRAJ46           TRAJ46           T	of oral mucosa in the ACM Day1 CDR3 CVVGDRCSALGRLHF(INKT) CALSEKSSGSWQLIF CAARNSGGSNYKLTF CALVPNTGGADRLTF CAMEDYGCSGNKLIF CAASSGSWQLIF CAASSGSWQLIF CAASSGSWQLIF CAAGGQAGCAF CALTAGSGGKLTL CAAGGQQGCSAKLIF CAAGCDQGCSAKLIF CAAGCDQGCSAKLIF CAAGCDQGCSAKLIF CAAGCDQGCSAKLIF CAAGCDQGCSAKLIF CAAGCDQGCSAKLIF CAACGACS CAPNTGNYKYVF CALSAPDAYKVIF CALSAPDAYKVIF CALSGRNVGDNSKLIW CAVSAGGADRLTF CAASGCACC CAVSAGCADRLTF CAASSACS CAVSAGCADRLTF CACASSACS CACSSACSACS CACSSACSACS CACSSACSACSACSACSACSACSACSACSACSACSACSAC	%Reads           2.29           1.49           1.23           0.99           0.92           0.80           0.69           0.68           0.61           0.53           0.55           0.54           0.53           0.52           0.51           0.50           0.48           0.48           0.46           0.46	Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19           20           21           22           23           24	TRA Ranking Top1           TRAV           TRAV11D           TRAV7-5           TRAV12-2           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV10-2           TRAV6D-7           TRAV60-7           TRAV60-7           TRAV14D-3/DV8           TRAV12-3           TRAV12-1           TRAV13D-1           TRAV13D-2           TRAV13D-2           TRAV12D-1           TRAV2-3           TRAV16D/DV11	-30 of cer TRAJ1 TRAJ18 TRAJ2 TRAJ37 TRAJ40 TRAJ31 TRAJ30 TRAJ30 TRAJ30 TRAJ36 TRAJ35 TRAJ27 TRAJ27 TRAJ27 TRAJ27 TRAJ27 TRAJ27 TRAJ32 TRAJ32 TRAJ32 TRAJ32 TRAJ22 TRAJ32 TRAJ32 TRAJ32	vical lymph nodes in the ACM Day CDR3 CVVGDRGSALGRLHF(iNKT) CAMSWWRTGGLSGKLTF CALLNQGGSAKLIF CALLNQGGSAKLIF CALGDFCNYKYVF CALGDFCNYKYVF CALDSNYQLIW CALETSSFSKLVF CALDSNYQLIW CALETSSFSKLVF CALDSNYQLIW CAASAGTGSKLTF CAARFVSALTF CAARFVSALTF CAARFVSALTF CALAYNTNTGKLTF CAARSSDSWQLIF CALIASSSFSKLVF CALLASSSFSKLVF CALLASSSFSKLVF CALESTSGSFNKMTF CAAREQGGGGNKLIF CAAREQGGGGNKLIF CAARESSFNKMTF CAARSGSFNKMTF CAISSFSKLVF CAARSGSFNKMTF CAISSSTALF CAARSGSFNKMTF CAISSSTALF	1 %Reads 0.22 0.06 0.06 0.06 0.06 0.06 0.05 0.04 0.04 0.04 0.04 0.04 0.04 0.03 0	
Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19           20           21           22           23           24           25	TRA Ranking           TRAV           TRAV11D           TRAV12D-1           TRAV10           TRAV10           TRAV13D-1           TRAV14D-3/DV8           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV51           TRAV5-3           TRAV5-1           TRAV5-1           TRAV5-1           TRAV5-1           TRAV12D-3           TRAV5-1           TRAV5-1           TRAV120-3           TRAV5-1           TRAV5-1           TRAV12D-3	Topl-30 c           TRAJ           TRAJ18           TRAJ22           TRAJ53           TRAJ54           TRAJ22           TRAJ32           TRAJ53           TRAJ54           TRAJ57           TRAJ64           TRAJ7           TRAJ8           TRAJ22           TRAJ33           TRAJ44           TRAJ57           TRAJ44           TRAJ7           TRAJ44           TRAJ57           TRAJ43           TRAJ44           TRAJ57           TRAJ44           TRAJ57           TRAJ44           TRAJ45           TRAJ45           TRAJ45           TRAJ43           TRAJ43           TRAJ44           TRAJ45           TRAJ45           TRAJ66           TRAJ26           TRAJ	of oral mucosa in the ACM Day1 CDR3 CVVGDRGSALGRLHF(INKT) CALSEKSSGSWQLIF CAARNSGGSNYKLTF CALVPNTGGADRLTF CALVPNTGGADRLTF CAMEDYGCSGNKLIF CAASSGSWQLIF CAASAGNYKYVF CAMERTGGADRLTF CAMEEDYAQGLTF CALTAGSGGKLTL CALGNSGGSNYKLTF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CAAJCGQGGSAKLIF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CAADGDQGSAKLIF CAADGDQGSAKLIF CALSGRNYGVVF CALSAPDAYKVIF CALSGRNVGDNSKLIW CAVSACGADRLTF CAVSAGGADRLTF CAADGQUFF CAADGQQFFF CAADGQQFFF	%Reads           2.29           1.49           1.23           0.99           0.92           0.80           0.69           0.68           0.61           0.53           0.52           0.52           0.52           0.52           0.51           0.50           0.49           0.48           0.48           0.46           0.45	Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19           20           21           22           23           24           25	TRA Ranking Top1           TRAV           TRAV11D           TRAV7-5           TRAV12-2           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV17           TRAV16D/DV11           TRAV10-7           TRAV14D-3/DV8           TRAV1-2           TRAV6D-3           TRAV14D-3/DV8           TRAV12-3           TRAV12-3           TRAV3D-1           TRAV7-2           TRAV13D-1           TRAV7-3           TRAV12D-1           TRAV13D-1           TRAV7-3           TRAV12D-1           TRAV13D-2           TRAV13D-1           TRAV7-3           TRAV12D-1           TRAV12D-1           TRAV12D-1           TRAV12D-1	-30 of cer TRAJ TRAJ18 TRAJ2 TRAJ20 TRAJ30 TRAJ30 TRAJ30 TRAJ33 TRAJ50 TRAJ33 TRAJ50 TRAJ35 TRAJ27 TRAJ27 TRAJ27 TRAJ22 TRAJ32 TRAJ4 TRAJ52 TRAJ22 TRAJ22 TRAJ22 TRAJ22 TRAJ22 TRAJ22	vical lymph nodes in the ACM Day CDR3 CVVGDRGSALGRLHF(iNKT) CAMSMWRTGCLSGKLTF CALLNQGGSAKLIF CALLNQGGSAKLIF CALGDCNYKYVF CALGDCNYKYVF CALGDCNYKYVF CALGDSNYQLIW CALETSSFSKLVF CALDSNYQLIW CALETSSFSKLVF CALDSNYQLIW CAASAGTGSKLTF CALASYAQGLTF CAARFVSALTF CALAYNTNTGKLTF CALAYNTNTGKLTF CAARSSFSKLVF CATEPGTNTGKLTF CAARSSFSKLVF CATEPGTNTGKLTF CAADGEQGGSAKLIF CAARLSGSFNKMTF CAALSEKSSGSWQLIF CAASSIGGRAMIF CAASSGGGRALIF	1 %Reads 0.22 0.06 0.06 0.06 0.05 0.04 0.04 0.04 0.04 0.04 0.04 0.03 0.03	
Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19           20           21           22           23           24           25           26	TRA Ranking           TRAV11D           TRAV11D           TRAV11D           TRAV12D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV5           TRAV5           TRAV5           TRAV5-1           TRAV5-1           TRAV5-1           TRAV5-1           TRAV5-1           TRAV5-1           TRAV12-3           TRAV5-1           TRAV5-1           TRAV5-1           TRAV12-3           TRAV12-3           TRAV12-3           TRAV5-1           TRAV5-1           TRAV12-3           TRAV12-3           TRAV12-3           TRAV12-3           TRAV9-3           TRAV9-3           TRAV9-3           TRAV9-3           TRAV9-3           TRAV14N-2           TRAV14N-2	Top1-30 c           TRAJ           TRAJ18           TRAJ22           TRAJ33           TRAJ24           TRAJ25           TRAJ26           TRAJ40           TRAJ45           TRAJ46           TRAJ57           TRAJ32           TRAJ33           TRAJ44           TRAJ57           TRAJ44           TRAJ57           TRAJ40           TRAJ41           TRAJ57           TRAJ40           TRAJ41           TRAJ45           TRAJ40           TRAJ41           TRAJ43           TRAJ45           TRAJ45           TRAJ40           TRAJ410           TRAJ43           TRAJ44           TRAJ45           TRAJ40           TRAJ43           TRAJ43           TRAJ44           TRAJ45           TRAJ46           TRAJ42           TRAJ42           TRAJ42           TRAJ42           TRAJ42           TRAJ42           TRAJ42	of oral mucosa in the ACM Day1 CDR3 CVVGDRGSALGRLHF(INKT) CALSEKSSCSWQLIF CAARNSGGSNYKLTF CALVPNTGGADRLTF CALVPNTGGADRLTF CAAGSGSSYKLIF CAASSGSWQLIF CAAGDYQGSGNKLIF CAAGEDYAQGLTF CALTAGSGGKLTL CALTAGSGGKLTL CAAGDQGGSAKLIF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CAALTGGADRLTF CAALTGGADRLTF CALSGRNYGVVF CALSAPDAYKVIF CALSGRNVGDNSKLIW CAVSAGGADRLTF CAVSMSYAQGLTF CAAVGQNFYF CAAYGYQNFYF	%Reads           2.29           1.49           1.23           0.99           0.92           0.80           0.69           0.68           0.61           0.58           0.51           0.52           0.52           0.52           0.51           0.50           0.49           0.48           0.48           0.46           0.45	Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19           20           21           22           23           24           25           26	TRA Ranking Top1           TRAV           TRAV11D           TRAV7-5           TRAV102           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV17           TRAV16D/DV11           TRAV16D/DV11           TRAV17           TRAV60-7           TRAV14D-3/DV8           TRAV5-2           TRAV60-3           TRAV14D-3/DV8           TRAV12-3           TRAV12-3           TRAV12-3           TRAV12-1           TRAV12-2           TRAV12-3           TRAV12-1           TRAV7-3           TRAV13D-1           TRAV70-2           TRAV13D-1           TRAV7-3           TRAV12-1           TRAV7-3           TRAV16D/DV11           TRAV16D/DV11           TRAV16/JDV8	-30 of cer TRAJ TRAJ18 TRAJ2 TRAJ37 TRAJ30 TRAJ30 TRAJ33 TRAJ30 TRAJ33 TRAJ50 TRAJ33 TRAJ50 TRAJ26 TRAJ27 TRAJ27 TRAJ50 TRAJ27 TRAJ50 TRAJ27 TRAJ5	vical lymph nodes in the ACM Day CDR3 CVVGDRGSALGRLHF(iNKT) CAMSWWRTGCLSGKLTF CALLNQGGSAKLIF CALLNQGGSAKLIF CALGPCNYKYVF CALDCPCNYKYVF CAMREYNNRVFF CANDSNYQLIW CALETSSFSKLVF CALDSNYQLIW CALETSSFSKLVF CALDSNYQLIW CAASAGTGSKLTF CALAYNNTGKLTF CAARFVSALTF CALAYNNTGKLTF CAARFVSALTF CALAYNNTGKLTF CAARSSFSKLVF CATEPGTNTGKLTF CAAGEQGGSAKLIF CAARLSGSFNKMTF CAARLSGSFNKMTF CALSEKSSGSWQLIF CALSEKSSGSWQLIF CAGSMTGANTGKLTF CAGSMTGANTGKLTF CAGSMTGANTGKLTF CAGSMTGANTGKLTF CAGSMTGANTGKLTF CAGSMTGANTGKLTF CAGSMTGANTGKLTF CAGSMTGANTGKLTF	1 %Reads 0.22 0.06 0.06 0.05 0.04 0.04 0.04 0.04 0.04 0.04 0.03 0.03	
Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19           20           21           22           23           24           25           26           27	TRA Ranking           TRAVID           TRAV11D           TRAV11D           TRAV10           TRAV10           TRAV13D-1           TRAV14D-3/DV8           TRAV14D-3/DV8           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV14-3           TRAV5-7/DV9           TRAV4-3           TRAV4-3           TRAV5-1           TRAV4-3           TRAV5-1           TRAV4-10V10           TRAV5-1           TRAV12-2           TRAV12-3           TRAV12-3           TRAV5-1           TRAV12-3           TRAV12-3           TRAV12-3           TRAV12-3           TRAV9-3           TRAV9-3           TRAV9-3           TRAV12-3           TRAV9-3           TRAV9-3           TRAV12-3           TRAV9-3           TRAV9-3           TRAV9-3           TRAV9-3           TRAV9-3           TRAV9-3           TRAV9-3	Topl-30 c           TRAJ           TRAJ18           TRAJ22           TRAJ33           TRAJ33           TRAJ32           TRAJ32           TRAJ33           TRAJ33           TRAJ40           TRAJ40           TRAJ41           TRAJ53           TRAJ44           TRAJ57           TRAJ40           TRAJ57           TRAJ40           TRAJ57           TRAJ40           TRAJ57           TRAJ40           TRAJ41           TRAJ57           TRAJ48           TRAJ43           TRAJ44           TRAJ57           TRAJ45           TRAJ40           TRAJ43           TRAJ44           TRAJ45           TRAJ45           TRAJ43           TRAJ44           TRAJ45           TRAJ45           TRAJ46           TRAJ47           TRAJ48           TRAJ49           TRAJ49           TRAJ49           TRAJ49           TRAJ49           T	of oral mucosa in the ACM Day1 CDR3 CVVGDRGSALGRLHF(INKT) CALSEKSSCSWQLIF CAARNSGGSNYKLTF CALVPNTGGADRLTF CALVPNTGGADRLTF CAABDYGCSGNKLIF CAASSGSWQLIF CAASSGSWQLIF CAAGDQGGGARLTF CAMEEDYAQGLTF CAMEEDYAQGLTF CAAGDQGGSAKLIF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CAADGDQGGSAKLIF CAADGDQGSAKLIF CAADGDQGSAKLIF CAADGDQGSAKLIF CAADGDQGSAKLIF CAADGDQGSAKLIF CAADGDQGSAKLIF CAADGDQGSAKLIF CALSRNVGDNSKLIW CALSGRNVGDNSKLIW CAVSAGGADRLTF CAAVSGCGQRVVF CAAVSGCGQYKVVF CAAYGQQNFYF CAAVSPCTGQYKVF CAAVGQNFYF CAAVSPCTGQYKVF CAAVTGYQNFYF	%Reads           2.29           1.49           1.23           0.99           0.92           0.80           0.69           0.68           0.61           0.58           0.57           0.56           0.54           0.52           0.51           0.52           0.51           0.49           0.48           0.48           0.48           0.45           0.45           0.45           0.43	Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           9           20           21           22           23           24           25           26           27	TRA Ranking Top1           TRAV           TRAV11D           TRAV7-5           TRAV12-2           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV17           TRAV6D-7           TRAV14D-3/DV8           TRAV6D-3           TRAV6D-3           TRAV14D-3/DV8           TRAV40-3           TRAV12-3           TRAV13D-1           TRAV13D-2           TRAV14D-3/DV8           TRAV14D-3/DV8           TRAV14D-3/DV8           TRAV14D-3/DV8           TRAV142-2	-30 of cer TRAJ TRAJ18 TRAJ2 TRAJ30 TRAJ30 TRAJ31 TRAJ33 TRAJ30 TRAJ33 TRAJ30 TRAJ37 TRAJ26 TRAJ37 TRAJ27 TRAJ27 TRAJ4 TRAJ57 TRAJ57 TRAJ57 TRAJ57 TRAJ22 TRAJ57 TRAJ21 TRAJ22 TRAJ57 TRAJ21 TRAJ22 TRAJ57 TRAJ21 TRAJ22 TRAJ57 TRAJ21 TRAJ22 TRAJ57 TRAJ21 TRAJ22 TRAJ57 TRAJ21 TRAJ22 TRAJ57 TRAJ21 TRAJ22 TRAJ57 TRAJ21 TRAJ22 TRAJ21 TRAJ22	vical lymph nodes in the ACM Day CDR3 CVVGDRGSALGRLHF(iNKT) CAMSWWRTGCLSGKLTF CALLNQGGSAKLIF CALLNQGGSAKLIF CALGDCNYKYVF CALGDCNYKYVF CALGPCNYKYVF CALMSNYQLIW CALETSSFSKLVF CALDSNYQLIW CALETSSFSKLVF CALDSNYQLIW CALSSTSKLTF CALGSNYQLIW CALSSAGTGSKLTF CALAYNINTGKLTF CAARFVSALTF CALAYNINTGKLTF CALAYNINTGKLTF CALASSFSKLVF CALEPCTNIGKLTF CAARGCGGGSAKLIF CAMEXTGSNEKLTF CAMEXTGSNEKLTF CAMSGGGGALIF CAARSGGGGALIF CAASSGGGRALIF CASSGGGGALIF	1 %Reads 0.22 0.06 0.06 0.06 0.05 0.04 0.04 0.04 0.04 0.04 0.04 0.04	
Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19           20           21           22           23           24           25           26           27           28	TRA Ranking           TRAV11D           TRAV11D           TRAV11D           TRAV11D           TRAV10           TRAV10           TRAV13D-1           TRAV14D-3/DV8           TRAV13D-1           TRAV14-3           TRAV5-7/DV9           TRAV5-1           TRAV5-1           TRAV12-2           TRAV12-3           TRAV13-1           TRAV14-1           TRAV13-1	Topl-30 c           TRAJ           TRAJ18           TRAJ22           TRAJ33           TRAJ345           TRAJ32           TRAJ32           TRAJ33           TRAJ45           TRAJ53           TRAJ53           TRAJ64           TRAJ55           TRAJ64           TRAJ55           TRAJ64           TRAJ55           TRAJ64           TRAJ75           TRAJ44           TRAJ55           TRAJ40           TRAJ56           TRAJ77           TRAJ45           TRAJ45           TRAJ44           TRAJ55           TRAJ45           TRAJ45           TRAJ45           TRAJ40           TRAJ30           TRAJ38           TRAJ42	of oral mucosa in the ACM Day1 CDR3 CVVGDRCSALGRLHF(INKT) CALSEKSSCSWQLIF CAARNSGGSNYKLTF CALVPNTGGADRLTF CAMEDYGGSGNKLIF CAASSGSWQLIF CAASAGNYKYVF CAMERTGGADRLTF CAMERTGGADRLTF CAABEDYAQGLTF CALTACSGGKLTL CALGNSGGSNYKLTF CAADGDQGGSAKLIF CAAJGDQGGSAKLIF CAAJGDQGGSAKLIF CAAJGDQGGSAKLIF CAASGGNYKVF CALSAPDAYKVF CALSAPDAYKVF CALSAPDAYKVF CALSAPDAYKVF CALSARVGDNSKLIW CAVSAGGADRLTF CAVSMSYAQGLTF CAVSMSYAQGLTF CAVSGGYGYFF CAASGGYFF CAASGGADRLTF CAVSGYAQGLTF	%Reads           2.29           1.49           1.23           0.99           0.61           0.58           0.57           0.56           0.51           0.52           0.51           0.52           0.51           0.52           0.51           0.52           0.51           0.52           0.51           0.52           0.51           0.43           0.48           0.46           0.45           0.45           0.43	Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19           20           21           22           23           24           25           26           27           28	TRA Ranking Top1           TRAV11D           TRAV11D           TRAV11D           TRAV7-5           TRAV12-2           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV17           TRAV6-7           TRAV50-3           TRAV6-7/DV9           TRAV6-7/DV9           TRAV6-7/DV9           TRAV6-3/DV8           TRAV12-3           TRAV12-3           TRAV12-3           TRAV12-3           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV7-3           TRAV16D/DV11           TRAV13D-1           TRAV7-3           TRAV14D-3/DV8           TRAV14D-3/DV8           TRAV12-2           TRAV12-2	-30 of cer TRAJ TRAJ18 TRAJ2 TRAJ37 TRAJ33 TRAJ40 TRAJ33 TRAJ33 TRAJ50 TRAJ26 TRAJ26 TRAJ27 TRAJ27 TRAJ31 TRAJ27 TRAJ31 TRAJ22 TRAJ4 TRAJ52 TRAJ25 TRAJ25 TRAJ25 TRAJ25 TRAJ26 TRAJ26 TRAJ26 TRAJ26	vical lymph nodes in the ACM Day CDR3 CVVGDRCSALGRLHF(iNKT) CAMSMWRTGGLSGKLTF CALLNQGGSAKLIF CALLNQGGSAKLIF CAMREGRVIW CALGDPGNYKYVF CALGDPGNYKYVF CALGDYNYQLIW CALETSSFSKLVF CANDSNYQLIW CAASAGTGSKLTF CAASSTGSKLTF CAASSTGSKLTF CAASSTGSKLTF CALAYNTNTGKLTF CALAYNTNTGKLTF CALAYNTNTGKLTF CAASSDSWQLIF CALRASSSFSKLVF CATEPGTNTGKLTF CAABGEQGGSAKLIF CAARSSCSWQLIF CAARSSCSWQLIF CAASSGSGRAKLIF CAASSGGGRALIF CAASSGGGRALIF CAASSGGGGAKLIF CAASSGGGGAKLIF CAASSGGGGAKLIF CAASSGGGGAKLIF CAASSGGGGALIF	1 %Reads 0.22 0.06 0.06 0.06 0.06 0.05 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.03 0.02 0.02 0.02 0.02	
Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19           20           21           22           23           24           25           26           27           28           29	TRA Ranking           TRAV11D           TRAV11D           TRAV11D           TRAV10           TRAV10           TRAV10           TRAV13D-1           TRAV14D-3/DV8           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV13D-1           TRAV14-3           TRAV5-7           TRAV4-3           TRAV9-3           TRAV4-3           TRAV5-1           TRAV5-1           TRAV12-5           TRAV12-5           TRAV12-3           TRAV7-1           TRAV13-1           TRAV13-1	Topl-30 c           TRAJ           TRAJ18           TRAJ22           TRAJ32           TRAJ32           TRAJ32           TRAJ32           TRAJ32           TRAJ32           TRAJ32           TRAJ45           TRAJ45           TRAJ44           TRAJ57           TRAJ45           TRAJ46           TRAJ47           TRAJ47           TRAJ48           TRAJ40           TRAJ41           TRAJ57           TRAJ40           TRAJ41           TRAJ57           TRAJ41           TRAJ43           TRAJ43           TRAJ43           TRAJ43           TRAJ43           TRAJ43           TRAJ44           TRAJ45           TRAJ46           TRAJ47           TRAJ48           TRAJ48           TRAJ48           TRAJ48           TRAJ48           TRAJ48           TRAJ48           TRAJ48           TRAJ49           TRAJ48           T	of oral mucosa in the ACM Day1 CDR3 CVVGDRCSALGRLHF(INKT) CALSEKSSCSWQLIF CAARNSGGSNYKLTF CALVPNTGGADRLTF CALVPNTGGADRLTF CAASSGSWQLIF CAASSGSWQLIF CAASAGNYKYVF CAMERTGADRLTF CAASAGRYKYVF CAMERTGADRLTF CAASGGKLTL CALTACSGGKLTL CALGNSGGSNYKLTF CAADGDQGGSAKLIF CAATGSGGKLTL CAADGDQGGSAKLIF CAAJCDQGGSAKLIF CAAJCADGDQGSAKLIF CAAJCADGQGSAKLIF CAAJCADGRUTF CALTAGADRLTF CALTAGADRLTF CALSAPDAYKVIF CALSAPDAYKVIF CALSARVGDNSKLIW CASAGGADRLTF CAASGGNSYLIF CAAJTGYQNFYF CAAYTGYQNFYF CAAYGQLTF CALPNTAQGLTF CALSGRNYQQLTF	%Reads           2.29           1.49           1.23           0.99           0.61           0.68           0.61           0.52           0.51           0.52           0.51           0.52           0.51           0.52           0.51           0.52           0.51           0.48           0.48           0.46           0.45           0.45           0.43           0.43	Rank           1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19           20           21           22           23           24           25           26           27           28           29	TRA Ranking Top1           TRAV11D           TRAV11D           TRAV11D           TRAV122           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV16D/DV11           TRAV17           TRAV60-7           TRAV60-7           TRAV60-3           TRAV6-7/DV9           TRAV6-3           TRAV12-3           TRAV12-3           TRAV12-3           TRAV12-3           TRAV13D-1           TRAV7-3           TRAV13D-2           TRAV13D-1           TRAV7-3           TRAV13D-1           TRAV7-3           TRAV14D-3/DV8           TRAV16D/DV11           TRAV16D/DV12           TRAV12-2           TRAV16D/DV12           TRAV12-3	-30 of cel TRAJ1 TRAJ18 TRAJ2 TRAJ33 TRAJ40 TRAJ33 TRAJ40 TRAJ33 TRAJ50 TRAJ35 TRAJ26 TRAJ27 TRAJ27 TRAJ27 TRAJ27 TRAJ27 TRAJ27 TRAJ22 TRAJ4 TRAJ57 TRAJ22 TRAJ57 TRAJ22 TRAJ57 TRAJ22 TRAJ57 TRAJ22 TRAJ57 TRAJ23	vical lymph nodes in the ACM Day CDR3 CVVGDRGSALGRLHF(iNKT) CAMSWWRTGGLSGKLTF CALLNQGGSAKLIF CALLNQGGSAKLIF CALGDPGNYKYVF CALGDPGNYKYVF CALGDPGNYKYVF CALGDSNYQLIW CALSTSFSKUF CANMDSNYQLIW CALSTSFSKUF CALGSNYQLIW CAASAGTGSKLTF CAASAGTGSKLTF CAASSTSWQLIF CAASAGTGSKLTF CALAYNTNTGKLTF CALAYNTNTGKLTF CALAYNTNTGKLTF CALAYNTNTGKLTF CAASSSDSWQLIF CALRASSFSKLVF CARECTONTGKLTF CAAGGEQGGSAKLIF CAASGGGRAMIF CALSEKSSGSWQLIF CACASGGGRAMIF CALSCSFNKMTF CALSCAGGGSAKLIF CAASGGGGAALIF CAASGGGGAKLIF CAASGGGGAKLIF CALSPCGGGGSAKLIF CALSPCGGGSAKLIF	'1           %Reads           0.22           0.06           0.06           0.06           0.06           0.06           0.06           0.06           0.06           0.06           0.06           0.06           0.06           0.06           0.03           0.04	

**Figure 6.** Ranking of the top 30 most frequently read TRA clonotypes (as a percentage) in the oral mucosa and cervical lymph nodes of the ICM and ACM mice at Day 1 post-challenge. Distributions of frequency (%) reads of amino acid sequences of CDR3 regions in the oral mucosa and cervical lymph nodes of the ACM mice revealed the presence of Cr-specific T-cells bearing TRAV12D-1-TRAJ22 (yellow shading). In both the oral mucosa and the cervical lymph nodes of the ICM and ACM mice, iNKT-cells (green shading) are highly expressed. N.D. = not detected.

## 3. Discussion

In this study, we successfully established a mouse model of intraoral Cr allergy and induced a delayed allergic response in the oral mucosa, building on previous studies documenting a Cr-induced allergic mouse model using the footpad skin or the auricle [15,20]. Recently, the usage of Cr in dental treatments, such as implants, and other intraoral treatments has increased. In a previous study, adverse effects were observed when local chromium concentrations were high owing to the release of particulate and soluble chromium released from implants [21]. However, the pathological mechanism of intraoral Cr allergy remains unclear because there is no established animal model of Cr allergy in the oral mucosa.

To our knowledge, this is the first study to clarify Cr-specific immune responses in the oral mucosa using a murine model of intraoral Cr allergy. In the ICM group, which was exposed to the external stimuli of Cr injections without sensitization, histopathological examination revealed a significant amount of inflammatory cell infiltration under the epithelium, as well as inflammatory reactions in the dermis and muscle layer at Day 1 postchallenge. In the ICM group at Day 7 post-challenge, there was little irritated inflammation at the site. The ACM group showed obvious spongiform edema and T-cell infiltration at Day 1 post-challenge in the injected epithelium. Intraepithelial spongiform edema is a defining feature of DTH [22]. By Day 7 post-challenge, the spongiform edema had decreased and T-cells had infiltrated the subepithelial layer. In the ACM group, F4/80+ macrophages infiltrated the basal epithelial and subepithelial layers at Day 1 post-challenge but then decreased until Day 7 post-challenge. Our Cr-induced allergic mouse model in the oral mucosa has characteristics resembling DTH; therefore, it may be appropriate for studying delayed allergic reactions in the oral mucosa. As regards the duration of acute ACD, previous studies have indicated that it develops between 24 and 48 h after initiation [23]. Initially, skin lesions are asymmetric and limited to the area of contact; later, they often spread or disseminate. In the case of severe reactions, swelling and blistering are observed. The major clinical differences between non-sensitized irritant contact dermatitis (ICD) and sensitized ACD are the more rapid onset of ICD and the tendency of ACD to spread. Characteristic widespread reactions are usually symmetric, although the primary reaction is not [23]. Metal allergy can be induced by either CD4+ or CD8+ T-cells, depending on the antigen processing pathway [9,24]. In this mouse model of intraoral Cr allergy, CD8+ T-cells accumulated in large numbers in ACM at Day 1 post-challenge, but this was not observed in control or ICM mice (Figure 3). These results suggest that sensitization had occurred and that CD8+ T-cells specific to Cr were induced in intraoral Cr-induced allergic mice. Another mouse model of metal allergy found that CD8+ T-cells accumulated at inflammatory sites, suggesting that these T-cells promote inflammation during the DTH induction stage [14].

We also compared the IL-1 $\beta$ , IFN- $\gamma$ , IL-4, and granzyme B expression levels in the oral mucosa of the control, ICM, and ACM mice (Figure 4). At Day 1 post-challenge, the levels of IFN- $\gamma$  expression in the ACM mice were significantly higher than those seen in the ICM mice. However, there were no differences in the levels of IL-4 expression between the ACM and ICM mice at Day 1 post-challenge. This indicates that the Cr-allergic immune response in the oral mucosa may be Th-1-biased at Day 1 post-challenge. CD8+ T-cells were reported as infiltrating the inflammatory site during metal allergy induction and producing IFN- $\gamma$  [14]. Furthermore, IL-1 $\beta$  induces Th-1 and Th-17 differentiation and stimulates cytokine production in T-cells and CD8+ T-cells residing in the epidermal tissue, which may increase IL-1 $\beta$  production via a positive feedback loop [25]. Our results were consistent with those of this study. According to a separate study, granzyme B expression was elevated in the skin of patients with metal allergy [26]. CD8+ T-cells are cytotoxic and kill target T-cells by releasing cytotoxic granules. Our findings indicate that IFN- $\gamma$  is the principal effector cytokine of Cr allergy in the oral mucosa. The apoptosis of keratinocytes induced by macrophages and CD8+ T-cells may also play a role in the pathogenesis of Cr allergy in the oral mucosa. We previously developed a mouse model of Cr-induced ACD

in the footpad of mice and found that allergic-specific T-cells used a specific TCR repertoire in Cr-induced ACD [15]. The infiltrating T-cells included iNKT-cells and Cr-specific T-cells with VA11-1/VB14-1 usage. In this study, we observed an accumulation of iNKT-cells in the inflamed mucosa of the ICM and ACM mice. These iNKT-cells help to amplify early immune responses [19,27]. The accumulation of iNKT-cells in the inflamed oral mucosa in Ni allergy suggests that iNKT-cells are involved in metal allergy [28]. In this study, we also observed the accumulation of Cr-specific T-cells bearing TRAV12D-1-TRAJ22 and iNKT-cells in the inflamed oral mucosa of Cr-allergic mice (Figures 5 and 6). This result contributes significantly to our understanding of antigen recognition by Cr-specific T-cells. Th1-type cytokines and cytotoxic molecules from iNKT-cells and Cr-specific Tcells are likely to be positively correlated with the pathogenesis of metal allergy in the footpads of mice. TCR repertoire and CDR3 sequencing analyses revealed a shared TCR repertoire expressing TRAV12D-1-TRAJ22 with the CDR3 sequence (CALSEKSSGSWQLIF) in the oral mucosa and lymph nodes at Day 1 post-challenge (Figure 6). In contrast to the highly restricted TRAV repertoire, oral mucosa-infiltrating T-cells displayed a relatively broad TRBV repertoire. As the TCR repertoire involved in Cr allergy differs between the oral mucosa, the footpad, and the ears, it is likely that organ-specific immune responses may occur during metal allergy. Furthermore, iNKT-cells were abundant in the ICM and ACM mice, while MAIT-cells were detected in the oral mucosa of the ACM mice at Days 3 and 7 post-challenge, whereas TRAV12D-1-TRAJ22-bearing T-cells were not (Figure S1). iNKT and MAIT-cells were found in high numbers in our previous research on cross-reactive metal allergy, suggesting that they may be involved in the development of cross-reactive metal allergy [29]. Consequently, the data on the TCR repertoire contribute to our understanding of the structural identity of antigenic determinants recognized by Cr-induced intraoral metal contact allergy.

In conclusion, we demonstrated that CD8+ T-cells infiltrated the oral mucosa during an allergic inflammatory response in a mouse model of metal allergy. We also identified clones of T-cells specific to Cr-induced allergy. Our analysis of the TCR repertoire demonstrated that restricted TRAV12D-1-TRAJ22 usage with the CDR3 amino acid sequence (CALSEKSSGSWQLIF) and broad TRBV might specifically recognize Ag in Cr allergy of the oral mucosa. In that case, the direct cloning of TCR genes from local sites of inflammation using this model would be a powerful tool for advancing our understanding of T-cell-mediated immune disease in metal allergy, and it would also provide new insights into Ag recognition by Cr-specific TCR in the oral mucosa.

#### 4. Materials and Methods

#### 4.1. Animals

*BALB/cAJcl* mice (4-week-old females) were purchased from CLEA Japan (Tokyo, Japan). All of the mice were in good health throughout the duration of the study and were given 1 week to acclimatize to their surroundings before the study began. At the beginning of the experiment, the mice were 5 weeks old. All of the mice were kept in plastic cages (with lids made of stainless-steel wire) and given ad libitum access to food and water. The mice were kept in our conventional animal facility with a temperature of 19–23 °C, a humidity of 30–70%, and a 12 h day/night cycle. During experiments, their appearance, their behavior, and the amount of food and water they consumed were monitored daily to ensure the health and comfort of all of the mice. All surgeries were performed using three different types of mixed anesthetics, and every effort was made to minimize animal suffering. All of the mice were euthanized by cervical dislocation under three different types of mixed anesthetics agents to prevent pain caused by tissue harvesting.

#### 4.2. Reagents

FUJIFILM Wako Pure Chemical Co., Ltd. was the supplier of high-purity CrCl<sub>2</sub> (>95%) (Osaka, Japan). Lipopolysaccharide (LPS) from *Escherichia coli* (O55:B5) prepared by phenol–water extraction was purchased from Sigma-Aldrich (St Louis, MO, USA). CrCl<sub>2</sub> and LPS

were dissolved in sterile saline (Otsuka Normal Saline, Otsuka Pharmaceutical Factory, Inc., Tokushima, Japan).

#### 4.3. Anesthetic Agents

The anesthetic was created by combining three medications. We purchased medetomidine hydrochloride from Nippon Zenyaku Kogyo Co., Ltd. (Fukushima, Japan), midazolam from Sandoz (Tokyo, Japan), and butorphanol tartrate from Meiji Seika Pharma Co., Ltd. (Tokyo, Japan). These drugs were kept at room temperature (RT). We combined doses of 0.3 mg/kg medetomidine hydrochloride, 4 mg/kg midazolam, and 5 mg/kg butorphanol tartrate. The concentration ratio of the three types of mixed anesthetic agents was determined according to data from a previous study [30]. Typically, 25 mL of anesthetic agent was prepared by combining 0.75 mL of medetomidine hydrochloride, 2 mL of midazolam, 2.50 mL of butorphanol tartrate, and 19.75 mL of sterile saline. All of the agents were diluted in sterile saline and stored in the dark at 4 °C. The mice were administered a volume of 10  $\mu$ L/g of body weight of the anesthetic mixture. The mixture of the three types of anesthetic agents was injected intraperitoneally into every mouse.

#### 4.4. Experimental Protocol for the Mouse Model of Cr-Induced Intraoral Metal Contact Allergy

We have developed an experimental protocol for the induction of metal allergy in the oral mucosa [28] based on a previous protocol for the induction of metal allergy in footpad skin. Mice were separated into three groups: ACM (n = 15), ICM (n = 15), and control (n = 15), with each group consisting of randomly selected mice. All experiments were performed in another room upon transfer from the animal holding area.

Sensitization: The mice received two intradermal injections of 125  $\mu$ L of 10 mM CrCl<sub>2</sub> and 10 g/mL LPS in sterile saline with a 7-day interval between injections. The ACM group was sensitized on the postauricular skin in the left and right ears. Seven days after the second sensitization, the mice were challenged for the first time.

Challenge for elicitation: 25  $\mu$ L of 10 mM CrCl<sub>2</sub> without LPS in sterile saline was used to elicit an immune response. The ACM mice were challenged by submucosal injection in the left and right buccal regions of the oral mucosa. The ICM mice were not sensitized, but they were challenged with CrCl<sub>2</sub>. The control mice were sensitized and then challenged with sterile saline.

#### 4.5. Measurement of Oral Mucosa Swelling

The swelling of the buccal region was measured before the challenge and at 1, 2, 3, 5, 7, 10, 12, and 14 days after the initial challenge using a Peacock Dial Thickness Gauge (Ozaki MFG Co., Ltd., Tokyo, Japan). The thickness of the buccal area oral mucosa was measured before and after the challenge, and the difference was recorded. The same experimenter performed all procedures on the mice while they were under anesthesia.

#### 4.6. Histological and IHC Analysis

For histological and immunohistochemical analyses, buccal oral mucosa samples were obtained from the control, ICM, and ACM mice. Furthermore, the tissue samples were immersed in 4% paraformaldehyde–lysine–periodate for 48 h at 4 °C. After a 10-min wash in PBS, fixed tissues were soaked in 5% sucrose/PBS for 1 h at 4 °C, 15% sucrose/PBS for 3 h at 4 °C, and finally, 30% sucrose/PBS overnight at 4 °C. The buccal mucosa tissues were snap-frozen by immersion in a mixture of acetone and dry ice in Tissue Mount (Chiba Medical, Saitama, Japan). Frozen sections were cut into 6  $\mu$ m thick cryosections and airdried on poly-L-lysine-coated glass slides. The HE stain was applied to cryosections for histological analysis. The cryosections were stained with anti-mouse F4/80 (1:1000; Cl-A3-1, Abcam, Cambridge, UK) and anti-mouse CD3 (1:500; SP7, Abcam) monoclonal antibodies for IHC analysis (mAbs). The F4/80 monoclonal antibody was used to detect mouse macrophage populations in many buccal oral mucosal tissues. The sections were incubated at RT for 30 min in PBS containing 5% normal goat/rabbit serum, 0.025% Triton X-100

11 of 14

(FUJIFILM Wako Pure Chemical, Osaka, Japan), and 5% bovine serum albumin (Sigma-Aldrich). Sections were incubated with primary mAbs for 1 h at RT. After three 5-min washes with PBS, intrinsic peroxidase was inhibited with 3%  $H_2O_2$  in methanol. After the tissue sections were soaked in distilled water, they were washed twice and incubated for 1 h at RT with a secondary antibody (biotinylated goat anti-hamster immunoglobulin G or biotinylated rabbit anti-rat immunoglobulin G). The sections were treated with Vectastain ABC Reagent (Vector Laboratories, Burlingame, CA, USA) for 30 min at RT, followed by 3,3-diaminobenzidine staining (0.06% diaminobenzidine and 0.03%  $H_2O_2$  in 0.1 M Tris–HCl, pH 7.6; FUJIFILM Wako Pure Chemical). Hematoxylin was used to counterstain tissue sections to visualize cell nuclei.

# 4.7. RNA Extraction

The buccal region of the oral mucosa in each mouse was freshly obtained and immersed immediately in RNAlater RNA Stabilization Reagent (Invitrogen, Carlsbad, CA, USA). Total RNA was extracted from the buccal region of the oral mucosa using the RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden, Germany) as directed by the manufacturer. Complementary DNA (cDNA) was synthesized from DNA-free RNA.

# 4.8. Quantitative Polymerase Chain Reaction

The expression levels of immune response-related genes, including T-cell-related CD antigens, cytokines, cytotoxic granules, and regulatory T-cell transcription factors, were measured using qPCR on a Bio-Rad CFX96 instrument (Bio-Rad, Hercules, CA, USA). Previously, specific primers for GAPDH, CD3, CD4, CD8, IFN-γ, Granzyme B, IL-4, and IL-1β were described [15,16,31]. The Prime Script RT reagent Kit (Takara Bio, Shiga, Japan) was used to convert newly isolated total RNA from the oral mucosa and submandibular lymph nodes into complementary DNA (cDNA). In a final volume of 10  $\mu$ L, the PCR contained 5  $\mu$ L SsoFast EvaGreen Supermix (Bio-Rad), 3.5 µL RNase/DNase-free water, 0.5 µL of 5 µM primer mix, and 1  $\mu$ L cDNA. The following cycling conditions were used: 30 s at 95 °C, followed by 50 cycles of 1 s at 95 °C and 5 s at 60 °C. At the conclusion of each protocol, a melting curve analysis from 70 °C to 90 °C was performed to confirm the homogeneity of the PCR products. All tests were performed three times, and the mean values were used to determine gene expression levels. Five 10-fold serial dilutions of each standard transcript were utilized to determine the absolute amount, specificity, and amplification efficiency of each primer set. Standard transcripts were generated through the in vitro transcription of the corresponding PCR product in a plasmid. DNA sequencing confirmed the nucleotide sequences using the CEQ8000 Genetic Analysis System (Beckman Coulter, Fullerton, CA, USA). Next, using an Agilent DNA 7500 Kit on an Agilent 2100 Bioanalyzer, their quality and concentration were determined (Agilent, Santa Clara, CA, USA). The expression of the GAPDH gene served as an internal control.

# 4.9. Mouse TCR Repertoire Analysis

Total RNA was extracted from the oral mucosa and cervical lymph nodes of the ICM and ACM mice at Day 1 post-challenge and from the oral mucosa of the ACM mice at Days 3 and 7 post-challenge. NGS was used to perform TCR repertoire analysis developed by Repertoire Genesis Inc. (Osaka, Japan [18]). As detailed in a previous report, an unbiased adaptor-ligation PCR was performed [32]. Superscript III reverse transcriptase was utilized to convert total RNA to cDNA (Invitrogen). Subsequently, double-stranded (ds) cDNA was synthesized, and an adaptor was ligated to the 5' end of the ds-cDNA before it was cut with the SphI restriction enzyme. For TCR $\alpha$ , PCR was performed using a P20EA adaptor primer and a TCR  $\alpha$ -chain constant region-specific primer (mCA1). The second PCR was conducted using the same PCR conditions and primers, mCA2 and P20EA. As regards TCR $\beta$ , the first and second primers used for PCR were mCB1 and mCB2, respectively. After Tag PCR amplification, index (barcode) sequences were amplified using a Nextera XT Index Kit v2 setA (Illumina, San Diego, CA, USA). Sequencing was performed using the paired-end Illumina MiSeq platform ( $2 \times 300$  base pairs [bp]). The repertoire analysis software of Repertoire Genesis, Inc. was used for automatic data processing, assignment, and aggregation. TCR (TRA and TRB) sequences were mapped to a reference sequence dataset from the international ImMunoGeneTics information system (IMGT) database (http://www.imgt.org, accessed on 1 November 2022 [33]). Nucleotide sequences of CDR3 regions ranged from a conserved cysteine at position 104 (Cys104) to a conserved phenylalanine at position 118 (Phe118), and the following glycine (Gly119) was translated into an amino acid sequence. A unique sequence read was defined as a sequence read with no identity in TRAV, TRAJ, and the deduced amino acid sequence of CDR3. The copy number of identical unique sequence reads in each sample was automatically counted and ranked by copy number using software for repertoire analysis. The percentage occurrence frequencies were calculated for sequence reads containing TRAV and TRAJ and for genes.

#### 4.10. Statistical Analysis

Statistically significant differences between the mean values of each experimental group were analyzed using the Kruskal–Wallis test followed by Dunn's multiple comparison tests. All analyses were performed using IBM SPSS Statistics version 24 (IBM, Armonk, NY, USA). A *p*-value of <0.05 was considered significant.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms24032807/s1.

**Author Contributions:** T.Y., K.K. (Kenichi Kumagai), Y.H. and R.S. conceived and designed the experiments; T.Y., K.K. (Kenichi Kumagai), R.M., K.N. and R.S. performed the experiments; T.Y., K.N., K.K. (Kazutaka Kitaura) and M.S. analyzed the data; T.Y., K.K. (Kazutaka Kitaura) and K.N. contributed reagents/materials/analysis tools; T.Y., K.K. (Kenichi Kumagai), M.S. and R.S. wrote the paper. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by the Japan Society for the Promotion of Science KAKENHI Grant-in-Aid for Scientific Research C Grant No. 19K10371.

**Institutional Review Board Statement:** All animal experiments in this study were carried out according to the relevant ethical requirements with approval from the committees for animal experiments at Tsurumi University (approval number: 21A025).

Informed Consent Statement: Not applicable.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author.

3

Conflicts of Interest: The authors declare no conflict of interest.

## Abbreviations

Cr	chromium
ACM	allergic contact mucositis
ICM	irritant contact mucositis
TCR	T-cell receptor
TRAV	TCRα-chain variable region
TRAJ	TCRα-chain joining region
TRBV	TCRβ-chain variable region
TRBJ	TCRβ-chain joining region
CDR3	complementarity-determining region

CD cluster of differentiation

#### References

- 1. Alinaghi, F.; Bennike, N.H.; Egeberg, A.; Thyssen, J.P.; Johansen, J.D. Prevalence of contact allergy in the general population: A systematic review and meta-analysis. *Contact Dermat.* **2019**, *80*, 77–85. [CrossRef] [PubMed]
- Zhang, X.; Wei, L.C.; Wu, B.; Yu, L.Y.; Wang, X.P.; Liu, Y. A comparative analysis of metal allergens associated with dental alloy prostheses and the expression of HLA-DR in gingival tissue. *Mol. Med. Rep.* 2016, 13, 91–98. [CrossRef] [PubMed]

- 3. Olms, C.; Schor, J.; Yahiaoui-Doktor, M. Potential Co-Factors of an Intraoral Contact Allergy-A Cross-Sectional Study. *Dent. J.* **2020**, *8*, 83. [CrossRef] [PubMed]
- 4. Kitagawa, M.; Murakami, S.; Akashi, Y.; Oka, H.; Shintani, T.; Ogawa, I.; Inoue, T.; Kurihara, H. Current status of dental metal allergy in Japan. *J. Prosthodont. Res.* 2019, 63, 309–312. [CrossRef]
- 5. Alnazzawi, A.A. Oral diseases associated with fixed prosthodontic restorations. Saudi Med. J. 2017, 38, 322–324. [CrossRef]
- Zemelka-Wiacek, M. Metal Allergy: State-of-the-Art Mechanisms, Biomarkers, Hypersensitivity to Implants. J. Clin. Med. 2022, 11, 6971. [CrossRef]
- Özkaya, E.; Elinç Aslan, M.S. Occupational allergic contact dermatitis: A 24-year, retrospective cohort study from Turkey. Contact Dermat. 2021, 85, 503–513. [CrossRef]
- 8. Hubler, W.R., Jr.; Hubler, W.R., Sr. Dermatitis from a chromium dental plate. Contact Dermat. 1983, 9, 377–383. [CrossRef]
- 9. van Wilsem, E.J.; Breve, J.; Savelkoul, H.; Claessen, A.; Scheper, R.J.; Kraal, G. Oral tolerance is determined at the level of draining lymph nodes. *Immunobiology* 1995, 194, 403–414. [CrossRef]
- 10. Davis, M.M.; Bjorkman, P.J. T-cell antigen receptor genes and T-cell recognition. Nature 1988, 334, 395–402. [CrossRef]
- Kumagai, K.; Horikawa, T.; Shigematsu, H.; Matsubara, R.; Kitaura, K.; Eguchi, T.; Kobayashi, H.; Nakasone, Y.; Sato, K.; Yamada, H.; et al. Possible Immune Regulation of Natural Killer T Cells in a Murine Model of Metal Ion-Induced Allergic Contact Dermatitis. *Int. J. Mol. Sci.* 2016, 17, 87. [CrossRef] [PubMed]
- Eguchi, T.; Kumagai, K.; Kobayashi, H.; Shigematsu, H.; Kitaura, K.; Suzuki, S.; Horikawa, T.; Hamada, Y.; Ogasawara, K.; Suzuki, R. Accumulation of invariant NKT cells into inflamed skin in a novel murine model of nickel allergy. *Cell. Immunol.* 2013, 284, 163–171. [CrossRef] [PubMed]
- Kobayashi, H.; Kumagai, K.; Eguchi, T.; Shigematsu, H.; Kitaura, K.; Kawano, M.; Horikawa, T.; Suzuki, S.; Matsutani, T.; Ogasawara, K.; et al. Characterization of T cell receptors of Th1 cells infiltrating inflamed skin of a novel murine model of palladium-induced metal allergy. *PLoS ONE* 2013, *8*, e76385. [CrossRef] [PubMed]
- Kumagai, K.; Matsubara, R.; Nakasone, Y.; Shigematsu, H.; Kitaura, K.; Suzuki, S.; Haneji, K.; Hamada, Y.; Suzuki, R. Possible involvement of invariant natural killer T cells and mucosal-associated invariant T cells in a murine model of titanium allergy. J. Oral Maxillofac. Surg. Med. Pathol. 2018, 30, 1–9. [CrossRef]
- Shigematsu, H.; Kumagai, K.; Kobayashi, H.; Eguchi, T.; Kitaura, K.; Suzuki, S.; Horikawa, T.; Matsutani, T.; Ogasawara, K.; Hamada, Y.; et al. Accumulation of metal-specific T cells in inflamed skin in a novel murine model of chromium-induced allergic contact dermatitis. *PLoS ONE* 2014, *9*, e85983. [CrossRef]
- Kitaura, K.; Fujii, Y.; Hayasaka, D.; Matsutani, T.; Shirai, K.; Nagata, N.; Lim, C.K.; Suzuki, S.; Takasaki, T.; Suzuki, R.; et al. High clonality of virus-specific T lymphocytes defined by TCR usage in the brains of mice infected with West Nile virus. *J. Immunol.* 2011, 187, 3919–3930. [CrossRef]
- 17. Kitaura, K.; Shini, T.; Matsutani, T.; Suzuki, R. A new high-throughput sequencing method for determining diversity and similarity of T cell receptor (TCR) alpha and beta repertoires and identifying potential new invariant TCR alpha chains. *BMC Immunol.* **2016**, *17*, 38. [CrossRef]
- Kitaura, K.; Yamashita, H.; Ayabe, H.; Shini, T.; Matsutani, T.; Suzuki, R. Different Somatic Hypermutation Levels among Antibody Subclasses Disclosed by a New Next-Generation Sequencing-Based Antibody Repertoire Analysis. *Front. Immunol.* 2017, *8*, 389. [CrossRef]
- 19. de Lima Moreira, M.; Souter, M.N.T.; Chen, Z.; Loh, L.; McCluskey, J.; Pellicci, D.G.; Eckle, S.B.G. Hypersensitivities following allergen antigen recognition by unconventional T cells. *Allergy* **2020**, *75*, 2477–2490. [CrossRef]
- Sitalaksmi, R.M.; Ito, K.; Ogasawara, K.; Suto, Y.; Itabashi, M.; Ueda, K.; Hirasawa, N.; Narushima, T.; Hendrijantini, N.; Kresnoadi, U.; et al. COX-2 induces T cell accumulation and IFN-gamma production during the development of chromium allergy. *Autoimmunity* 2019, 52, 228–234. [CrossRef]
- 21. Jumina, J.; Harizal, H. Dermatologic Toxicities and Biological Activities of Chromium. In *Trace Metals in the Environment-New* Approaches and Recent Advances; IntechOpen: London, UK, 2019; pp. 1–22. [CrossRef]
- Tanei, R.; Hasegawa, Y. Immunological Pathomechanisms of Spongiotic Dermatitis in Skin Lesions of Atopic Dermatitis. *Int. J. Mol. Sci.* 2022, 23, 6682. [CrossRef]
- Novak-Bilic, G.; Vucic, M.; Japundzic, I.; Mestrovic-Stefekov, J.; Stanic-Duktaj, S.; Lugovic-Mihic, L. Irritant and Allergic Contact Dermatitis-Skin Lesion Characteristics. Acta Clin. Croat. 2018, 57, 713–720. [CrossRef]
- 24. Scadding, G.; Durham, S. Mechanisms of sublingual immunotherapy. J. Asthma 2009, 46, 322–334. [CrossRef]
- 25. Yeung, K.; Mraz, V.; Geisler, C.; Skov, L.; Bonefeld, C.M. The role of interleukin-1beta in the immune response to contact allergens. *Contact Dermat.* **2021**, *85*, 387–397. [CrossRef]
- Yawalkar, N.; Hunger, R.E.; Buri, C.; Schmid, S.; Egli, F.; Brand, C.U.; Mueller, C.; Pichler, W.J.; Braathen, L.R. A Comparative Study of the Expression of Cytotoxic Proteins in Allergic Contact Dermatitis and Psoriasis. *Am. J. Pathol.* 2001, 158, 803–808.
   [CrossRef]
- Kanda, M.; Yamanaka, H.; Kojo, S.; Usui, Y.; Honda, H.; Sotomaru, Y.; Harada, M.; Taniguchi, M.; Suzuki, N.; Atsumi, T.; et al. Transcriptional regulator Bhlhe40 works as a cofactor of T-bet in the regulation of IFN-gamma production in iNKT cells. *Proc. Natl. Acad. Sci. USA* 2016, 113, E3394–E3402. [CrossRef]

- Nakasone, Y.; Kumagai, K.; Matsubara, R.; Shigematsu, H.; Kitaura, K.; Suzuki, S.; Satoh, M.; Hamada, Y.; Suzuki, R. Characterization of T cell receptors in a novel murine model of nickel-induced intraoral metal contact allergy. *PLoS ONE* 2018, 13, e0209248. [CrossRef]
- Shigematsu, H.; Kumagai, K.; Suzuki, M.; Eguchi, T.; Matsubara, R.; Nakasone, Y.; Nasu, K.; Yoshizawa, T.; Ichikawa, H.; Mori, T.; et al. Cross-Reactivity of Palladium in a Murine Model of Metal-Induced Allergic Contact Dermatitis. *Int. J. Mol. Sci.* 2020, 21, 4061. [CrossRef]
- 30. Kawai, S.; Takagi, Y.; Kaneko, S.; Kurosawa, T. Effect of three types of mixed anesthetic agents alternate to ketamine in mice. *Exp. Anim.* **2011**, *60*, 481–487. [CrossRef]
- Fujii, Y.; Kitaura, K.; Nakamichi, K.; Takasaki, T.; Suzuki, R.; Kurane, I. Accumulation of T-cells with selected T-cell receptors in the brains of Japanese encephalitis virus-infected mice. *Jpn. J. Infect. Dis.* 2008, 61, 40–48.
- Yoshida, R.; Yoshioka, T.; Yamane, S.; Matsutani, T.; Toyosaki-Maeda, T.; Tsuruta, Y.; Suzuki, R. A new method for quantitative analysis of the mouse T-cell receptor V region repertoires: Comparison of repertoires among strains. *Immunogenetics* 2000, 52, 35–45. [CrossRef] [PubMed]
- Lefranc, M.P.; Giudicelli, V.; Ginestoux, C.; Jabado-Michaloud, J.; Folch, G.; Bellahcene, F.; Wu, Y.; Gemrot, E.; Brochet, X.; Lane, J.; et al. IMGT, the international ImMunoGeneTics information system. *Nucleic Acids Res.* 2009, *37*, D1006–D1012. [CrossRef] [PubMed]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.